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Hyperammonaemia is not an infrequent presentation in the newborn or neonatal 
period. While the majority are transitory in nature and due to infective processes 
or liver pathology/immaturity, a significant number are due to defects in enzymes 
of the urea cycle. This cycle has evolved to cope with waste nitrogen disposal and 
the de novo synthesis of arginine. There are five distinct enzymatic steps in the 
urea cycle, and defects in each, result in a biochemically distinct disease. Four of 
these diseases, deficiencies of carbamyl phosphate synthetase (CPS), ornithine 
transcarbamylase (OTC), argininosuccm1c acid synthetase (ASS), and 
argininosuccinate lyase (ASL) can present dramatically within the first 24 to 48 
hrs of life with progressive lethargy, hypothermia and apnea, all related to very 
high plasma ammonia levels. These diseases may also present later in infancy, 
childhood and adulthood with hyperammonemia and episodic mental status 
changes. The fifth defect, arginase deficiency presents as progressive spastic 
quadriplegia and mental retardation but with milder elevation of blood ammonia 
levels. The molecular genetics of these disorders in South Africans has not been 
explored and there is thus very little information on phenotype/genotype 
relationships, specific for citizens of this country. This study aims to correct this 
imbalance and has concentrated initially on OTC deficiency, which is X-linked 
and therefore the most common defect encountered. Initial work on this project 
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1.1 Inherited metabolic diseases 
This study deals with deficiencies of one of the enzymes of the urea cycle, and 
which fall into the category of inherited metabolic diseases (IMDs ), sometimes 
referred to as inborn errors of metabolism (IEMs). These are largely monogenic 
disorders in that they are caused by the absence or dysfunction of a single gene 
product. As a group, they differ significantly from the chromosomal disorders 
where entire chromosomes or sections of chromosomes can be duplicated or lost 
from the human genome. In these instances, many contiguous genes can be 
duplicated or removed, sometimes resulting in unusual and complex metabolic 
derangements. (Harley E, 2000) 
The number of genes coding for enzymes in the human genome must number in 
the thousands, which raises the theoretically possibility of a corresponding 
number of IMDs. Reviews attempting to deal with just the portion of known 
enzymes deficiencies, have run to several volumes as typified by the 4 volume set 
"The Metabolic and Molecular Bases of Inherited Disease" (Scriver, C.R. et al 
2000). Given this context, the best compromise for this thesis is to record the 
general principles of the genetics, diagnosis, and treatment. (URL. 1) 
1.1.1 General concepts 
A typical metabolic pathway might show substrate A being converted to product, 
C through an intermediate B: 
A ., B C 
Should there be a block in the conversion of B to C, then an alternative pathway 
may be activated with B being metabolized to products D and E: 
A ., B ,'>/ 111> C 
l 
D ., E 
The metabolic consequences of an enzymatic block in the conversion of B to C, 
may be due to excess of precursors (A and B), the absence of product (C), or 
excessive amounts of alternate products (D and E). Their impact will vary 
between individuals as the degree of enzyme loss, kinetics of alternate pathways, 
and endogenous production of precursors differs between patients. The 
phenotype for a given disorder can thus be quite variable. Both exogenous and 
endogenous factors, which cause an increased metabolic flux through the 
defective pathway, can result in metabolic crisis and therefore, clinical 
deterioration. Endogenous catabolism generates the bulk of metabolites and 
becomes prominent in catabolic episodes induced by illness, fever, and starvation. 
These situations thus often precipitate or aggravate IMDs. (URL. 1) 
1.1.2 Classification of IMDs 
IMDs have many classification schemes, with one of the most prominent dividing 
the disorders into categories of cellular intoxication, energy deficiency, and of 
mixed types. Cellular intoxication occurs in disorders such as those involving the 
urea cycle enzymes or amino acid metabolism, and lysosomal function. In these 
cases, cells are poisoned by either the accumulation of small molecules which 
inhibit other metabolic pathways, lower intracellular pH etc, or by the 
accumulation of large molecules such as lipids or polysaccharides, which 
precipitate in the cytoplasm. Energy deficient disorders, such as pyruvate 
dehydrogenase deficiency (PDH) or medium chain acyl-CoA dehydrogenation 
deficiency (MCAD) exert their effects by depriving cells of the energy they need 
to function properly; this occurs through deprivation of substrates for the citric 
acid cycle. The mixed category is self explanatory and includes disorders such as 
the peroxisomal defects. (URL. 1) 
1.1.3 Genetics 
Most IMDs are autosomal recessive, occurring when an individual inherits two 
alleles with defects at a specific locus. This occurs infrequently in the general 
population but at a heightened frequency in unions between related individuals 
ie in consanguineous marriages. Others are inherited as X-linked recessive and 
2 
are more prominent as only one defective allele leads to disease in males. 
Examples include haemophilia, deficiencies m Glucose-6-phosphate 
dehydrogenase (G6PD) (causes a haemolytic anaemia), Duchenne muscle 
dystrophy and OTC ( ornithine transcarbamylase ), which is the focus of this 
thesis. 
In X-linked recessive disorders, hemizygous males are almost always 
symptomatic whereas carrier females may or may not present with clinical 
symptoms depending on their lyonization patterns. Carrier females have a 50% 
risk of passing the gene onto their children. Theoretically then, half of the boys 
could be affected while half the daughters could be carriers. 
1.1.4 Genes and IMDs 
Recently, recombinant DNA technology (RDT) has shown new ways to understand, 
diagnose and treat inherited diseases. RDT has relevance to IMDs in three ways; 
firstly, both normal and mutant genes can be cloned and studies; secondly, the 
technology provides novel and powerful diagnostic procedures and thirdly, 
treatment, through gene therapy, is now available to replace or insert copies of a 
normal gene to compensate for the defective gene. (Harley E, 2000) 
1.2 The urea cycle 
1.2.1 Overview 
Urea is the chief nitrogenous excretion product of mammals. It is largely 
synthesized in the liver and involves a series of 5 reactions that are distributed 
between the mitochondria and the cytosol. This series of reactions is known as the 
Urea Cycle or the Krebs-Hensleleit Cycle. (URL. 2) 
Most of the nitrogenous waste comes from the breakdown of amino acids and this 
occurs by deamination, which results in the production of ammonia (NH3). 
Ammonia is very toxic and its continued accumulation in the body is fatal. 
However, the liver contains a system of carrier molecules and enzymes that quickly 
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convert the ammonia into urea for excretion by the kidneys. A second function of 
the urea cycle is the de novo synthesis of arginine. (Brusilow and Horwich, 1995) 
High protein diets are particularly demanding of the urea cycle as the high nitrogen 
excess must be excreted. This is achieved by up regulation of the genes of the urea 
cycle. If these diets persist then 20-fold or greater increases in enzymes 
concentrations can be encountered. Elevated cycle enzymes are also found in 
situations of starvation when muscle breakdown accelerates. (URL. 2). 
1.2.2 Biochemistry 
The essential features of the urea cycle reactions are depicted in figure 1 and can be 
described as follows: Carbarnyl Phosphate synthetase (CPS), an enzyme from the 
mitochondrial matrix, catalyzes the biosynthesis of Carbarnyl Phosphate (CP) from 
ammonia and bicarbonate. Ornithine which is found in the cytosol is then 
transported to the mitochondrial matrix where it is condensed with CP to produce 
citrulline. This reaction is catalyzed by OTC and the energy for this reaction to take 
place is provided by the high-energy anhydride of CP. Citrulline is the transported 
to the cytosol, where it is condensed with aspartate to form argininosuccinate. This 
reaction is catalyzed by argininosuccinate synthetase (ASS). The cytosolic enzyme 
argininosuccinate lyase (ASL), leads to the production of arginine and fumarate. In 
the final step of the cycle, arginase cleaves urea from arginine, generating ornithine. 
Ornithine is then transported back to the mitochondrial matrix for another round of 
urea synthesis. A total of 3 A TPs and phosphates are consumed during the reaction 













asp art ate 1t 1996 M .W .Kirg 
Cytosol 
Figure. 1. Schematic illustration of the urea cycle. The reactions of the urea cycle 
that occur in the mitochondrion are contained in the oval. (Taken from URL 2) 
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1.2.3 Disorders 
Urea cycle disorders are caused by the deficiency or catalytic inactivity of one of the 
enzymes in the urea cycle. In these disorders, nitrogen accwnulates in the form of 
ammonia, which is highly toxic to the brain, and interferes with energy production 
and with the normal metabolism of neurotransmitters. Moderate elevations of blood 
ammonia of 100 to 200 µmol/L (normal < 50 µmol/L) are usually associated with 
clinical symptoms of lethargy and vomiting, whereas higher concentrations can 
result in diffuse brain edema, coma, and death. There are two forms in which 
ammonia is found in body fluids, ionized (NHi 1, and non-ionized (NH3). The 
second (non-ionized) form is more diffusible and therefore more toxic. When taking 
into consideration the ammonia dissociation constant (pK of 8.95), when the body 
fluids become more alkaline, the equilibriwn will shift towards NH3, Therefore 
increasing the toxicity even more. (Tuchman et al, 1992) 
The exact incidences of urea cycle disorders are under estimated, because many 
infants die without a definitive diagnosis. (URL. 3) 
1.2.3.1 Symptoms and signs 
Symptoms for urea cycle disorders appear not only in the neonatal period, but also in 
early childhood and adulthood. In the neonatal period these include feeding 
difficulties, lethargy, respiratory distress, impairment of consciousness, vomiting 
convulsions, and coma. Boys are more commonly affected as a result of OTC 
deficiency, which is X-linked. 
Presentation in the neonatal period is fatal without treatment by dialysis, protein 
restriction and benzoate administration. Childhood or delayed onset can be seen in 
both boys and girls, but is less frequent in girls who are carriers for OTC deficiency. 
Childhood onset symptoms include hyperactive behavior, refusal to eat meat or other 
high-protein foods, vomiting, lethargy, delirium. In the absence of diagnosis and 
treatment, coma and death may ensue. 
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Presentation in adulthood, usually involves stroke-like symptoms, episodes of 
lethargy and delirium, and are likely to be referred to a neurologist or a psychiatrist. 
When these symptoms occur in adults, without proper treatment, individuals are at 
the risk for permanent brain damage, coma and death. Adult onset is more common 
in women who are carriers for OTC deficiency. (Gordon, 2003 and URL 2) 
1.2.3.2 Clinical Presentation and Management 
OTC deficiency has been reported at a frequency of about 1/30 000 live births 
(URL. 4). The phenotypes in males and females have a spectrum of severities. 
Males with little or no OTC activity present with severe, intractable 
hyperammonemia beginning several days after birth and proceed rapidly to coma 
and death. Affected fetuses are protected in the womb by the dialyzing effect of 
the maternal circulation while the delay in development of symptoms after birth is 
related to minimal protein ingestion in the perinatal period (Brusilow and 
Horwich, 1995). Hyperammonemia eventually ensues, given the body's failure to 
incorporate nitrogen into urea in the presence of protein in the diet. 
"Partial OTC deficiency in males ( due to mutations, which do not entirely 
inactivate the OTC gene product), may produce chronic mild hyperammonemia, 
associated with variable degrees of developmental delay, or may manifest during 
periods of illness or prolonged fasting, which lead to a catabolic state" (Maestri et 
al., 1998). Most female carriers are not severely affected, and the severe neonatal 
course is not seen in female infants. Females do not usually have any symptoms 
and only experience nausea following high protein meals. Occasional carriers 
develop lethal hyperammonemia in response to severe metabolic stress, such as 
surgery. In presenting females, skewing of X-inactivation is the underlying cause. 
Here, changes in the proportion of active normal X chromosomes versus active 
chromosome bearing the OTC mutation is the major determinant of residual 
activity. Lyonisation patterns will differ in female siblings and hence severity in 
one daughter does not predict severity in another. 
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Plasma ammorua concentrations between 1000 and 2000µmol/L (normal 
<50µmol/L) usually accompanies presentation in the neonatal period. Blood urea 
is usually low and blood gas analysis shows signs of respiratory alkalosis, caused 
by hyperventilation, stimulated by ammonia effects on the brain. Liver function is 
generally unaffected with enzyme concentrations in the normal to mildly elevated 
range (Tuchman et al, 1992). 
Hemizygous males or heterozygous females having partial enzyme deficiencies 
normally present later in life with a clinical picture resembling Reye's syndrome. 
The clinical picture of these patients includes the following; protein intolerance, 
severe vomiting, lethargy during viral illness, Reye's disease-like episodes and 
developmental delay. These patients often restrict themselves from food that is 
high in protein. "Disorders that are treated with valproic acid may unveil a 
previously undiagnosed urea cycle defect, where the mitochondrial toxicity 
precipitates hyperammonemia in the patient." (Tuchman et al, 1992) 
Hair and skin changes (rashes) have been reported and are thought to be a result of 
arginine deficiency or an imbalance of other amino acids. "Acute 
hyperammonemia in children and adults even in the range of 200 to 500µmol/L is 
extremely dangerous, as it can progress rapidly to irreversible brain edema and 
herniation, whereas newborns with extreme hyperammonemia tend to be more 
resistant to irreversible brain edema, possibly because of open skull sutures 
accommodating brain swelling." (Tuchman et al, 1992 and Gordon, 2003) 
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Management 
The treatment of urea cycle disorders requires attention to the amount of protein 
ingested as it is necessary to provide essential amino acids for cell growth and 
development, and at the same time ensuring that excessive amounts of ammonia are 
not formed. Protein restriction is thus used in conjunction with scavengers such as 
sodium benzoate and sodium phenylacetate, which provide alternative pathways for 
the removal of ammonia. These agents are usually given by way of tube feedings of 
nasogastric tubes. Most children thus suffer a great deal of distress in taking this 
medication, which is often accompanied by amino acid therapy. Frequent 
monitoring of blood ammonia levels is required and frequent hospitalizations are 
often necessary for control of the disorder. (URL. 3, Gordon, 2003) 
Because of the generally poor prognosis for affected individuals, there has been 
considerable effort placed on developing new treatment approaches. The current 
focus is on liver transplantation and gene therapy where both have been tried, first in 
an animal model (the sparse fur spj!Y mouse) and then in humans (Batshaw et al 
1999; Raper et al 2003). 
1.2.3.3 Biochemical testing for carrier detection 
Two indicators of possible carrier status are an increased plasma glutamine 
concentration and an increased orotic acid excretion in the urine. There are three 
biochemical tests that may be helpful in determining carrier status when pedigree 
analysis is not informative. These tests are; 1) the allopurinol test; 2) the protein 
tolerance test and 3) the alanine tolerance test. Both the later tests have been 
abandoned because of the high protein meals are often risks for hyperammonemia 
and low sensitivities. (Brusilow and Horwich, 1995) 
The allopurinol test, which measures orotic acid excretion following allopurinol 
administration, appears to be the safest and most sensitive in post pubertal girls. The 
implication of this test for carrier detection in pre-pubertal girls has yet to be 
determined. 
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The allopurinol test relies on the altered function of hepatocytes in which the 
mutant allele is expressed. Carbamyl phosphate accumulates and is shunted out of 
these mitochondria of the cells into the cytosol, where pyrimidine synthesis is 
stimulated (Fig. 2). One of the metabolites in the pyrimidine pathway, orotidine, 
accumulates due to the inhibition of orotidine monophosphate decarboxylase, by 
oxypurinol monophosphate, an allopurinol derivative. The enzymatic block further 
leads to orotic acid overproduction, which can be detected by urine analysis. In a 
study by Maestri et al, 1998, the sensitivity of this test in 3 7 women identified, as 
obligate heterozygotes by pedigree analysis was 0.92. The specificity of this test 
was 1.00, as none of the normal control women had a positive test. "The sensitivity 
and specificity of the allopurinol test is substantially lower when orotate is measured; 
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Figure 2. The relation of intramitochondrial and cystolic carbamyl phosphate to 
pyrimidine biosynthesis and allopurinol metabolism m ornithine 
carbamyltransferase-deficient hepatocytes. (Brusilow and Horwich, 1995) 
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The most reliable way to determine carrier status is at the molecular level, by 
defining the mutation of the proband and testing for a specific mutation in the 
mother and other female family members. However, one has to be confident that the 
mutation is a deleterious one and not a polymorphism. In families with an affected 
female, testing the DNA of the father could help to establish the mutation as a 
polymorphism, if inheritance from an asymptomatic father can be demonstrated. 
Finding that the mutation occurred spontaneously in a family member increases the 
likelihood that it is deleterious. (Tuchman et al, 1992, Leibundgut et al, 1996) 
1.2.3.4 Linkage analysis in Carrier testing and Prenatal Diagnosis 
Microsatellite markers have proved to be highly informative markers for genetic 
mapping and linkage analysis. They are tandem repeats of 2 - 6 bp that occur 
abundantly and at random throughout most eukaryotic genomes. The length of the 
repeat regions is usually less than 100 bp and as they are flanked by unique DNA 
sequence, they can be amplified in vitro using PCR. They display considerable 
polymorphism due to variation in the number of repeat units and are sufficiently 
stable to be used in genetic analyses. (Hearne, C.M., et. al. , 1992). Linkage analysis 
can be a highly accurate alternative to mutation-specific diagnosis for families in 
which a firm diagnosis of OTC has been established, with no mutation found. This 
method is an indirect method of diagnosis that exploits the tendency of genes and 
markers that lie close together on a chromosome to be transmitted from parent to 
child with no recombination. Using linkage analysis for the diagnosis of OTC is 
relevant, as there are many polymorphisms in and near the OTC gene and 
recombination in this area can prevent mutations from being transmitted to future 
generations. In kindreds with more than one affected family member, this method 
can be used to determine which alleles co-segregated with the disease. When found 
that the fetus bears the disease-associated allele, it is extremely likely that the fetus is 
affected. The accuracy of this method is approximately 99%. The main limitation 
on linkage-based diagnosis is it' s use in kindreds with a single affected individual. 
One third of singleton affected offspring should be new mutants provided that the 
male and female mutation rates are equal (Bale, A.E, 1999). Increasing use of 
mutation-specific diagnosis is providing direct data addressing the frequency of new 
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mutations. 
Linkage analysis can also be used to identify an unaffected fetus in kindreds with a 
single affected person. If the fetus can be shown to have inherited a different OTC 
locus to the affected child then it is not at risk for OTC deficiency. However, in 
situations of identity, this linkage analysis becomes uninformative (Bale, A. E, 1999) 
1.2.3.5 Laboratory diagnosis of OTC deficiency 
Diagnosis of OTC deficiency requires the following has to be considered. Firstly, the 
blood ammonia level has to be determined. Secondly, plasma amino acid 
concentrations should be measured, especially citrulline. Thirdly, urinary orotic acid 
concentrations should be checked and fourthly, a liver biopsy could be done to 
measure OTC activity. OTC and CPS deficiency can be distinguished from the 
ASL, ASS and arginase deficiencies by plasma amino acid analysis. Citrulline 
concentrations in CPS and OTC deficiency are low to zero as the defect in both 
precedes citrulline synthesis. In contrast, citrulline concentrations are elevated in 
ASS deficiency while high concentrations of argininosuccinate and its anhydrides 
are found in ASL deficiency. OTC can be separated from CPS deficiency by the 
determination of urinary orotic acid or orotidine levels. Both these metabolites are 
elevated in the former and are absent in the latter (Burton, B.K, 1998). 
A flowchart for the differentiation of conditions producing significant 
hyperammonemia in the newborn is presented in Fig. 3. The timing of the onset of 
the symptoms may provide important information. Urine organic acid analysis 
should always be obtained, regardless of whether acidosis is present. Metabolic 
acidosis is not a typical feature of the urea cycle defects. Plasma amino acid analysis 
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Fig. 3. Flowchart for the differentiation of conditions associated with neonatal 
hyperammonemia. ASA indicates argininosuccinic acid; CPS, carbarnyl phosphate 
synthetase; THAN, transient hyperammonemia of the newborn. (Burton, B. K., 
1998) 
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1.2.3.6 Molecular genetics 
Five urea cycle defects have been described. Four of them, deficiencies of carbamyl 
phosphate synthetase (CPS), omithine transcarbamylase (OTC), argininosuccinic 
acid synthetase (ASS), and argininosuccinase acid lyase (ASL), are characterized by 
signs and symptoms induced by the accumulation of ammonia and glutamine. The 
fifth defect, arginase deficiency (AG) differs by presenting with progressive spastic 
quadriplegia and mental retardation, and hyperammonernia that is not as severe or as 
common in the other four diseases. (Brusilow and Horwich, 1995) 
Four of these disorders are transmitted genetically as autosomal recessive traits. 
One of these defects, Omithine transcarbamylase deficiency is inherited as an X-
linked condition, where mostly boys are affected. (URL. 3) 
1.3 OTC deficiency 
1.3.1 The OTC gene 
1.3.1.1 Mapping 
The OTC gene has been mapped to the short arm of the X chromosome on band Xp 
21.1 proximal to the Duchenne-Becker muscular dystrophy gene (Fig. 4). Other 
genes in this proximity are those for retinitis pigmentosa, chronic granulomatous 
disease, adrenal hypoplasia, glycerol kinase deficiency and Norrie disease. Large 
deletions in the area around the OTC gene could thus result in contiguous gene 
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Figure 4. Schematic map of the X chromosome and the genes (p arm) mapped to 
it. (URL. 5) 
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1.3.1.2 Organisation and structure 
The OTC gene (Fig. 5) was cloned and sequenced in 1984 (Horwich A.L, et al, 
1984). It spans about 80 kb and contains 10 exons and 9 introns. Exons vary in size 
from 154bp (exon 5) to 54bp (exon 7) while introns vary from 21.7kb (intron 4) to 
80bp (intron 7) in size. (Tuchman et al, 1998) 
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Figure 5. Schematic illustration showing the structure of the OTC gene. (Taken 
from URL. 6) 
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1.3.1.3. The synthesis, structure and function of the OTC protein 
Toe OTC enzyme is a trimer with three active sites per holoenzyme molecule. The 
messenger RNA of the OTC gene contains 1062 translatable bases, which encode 
the synthesis of a precursor OTC protein that consists of 354 amino acids and a 
molecular weight of 40 000 daltons. Toe amino terminus of the OTC protein 
contains a 32 amino acid leader sequence, which contains eight basic amino acids 
and no acidic amino acids. Toe leader sequence is important for binding to the 
mitochondrial membrane, incorporation into the mitochondrial matrix and 
intramitochondrial sorting. It is finally cleaved by a neutral protease to produce a 
mature polypeptide of 36 000 daltons, which is the catalytic unit of the OTC enzyme 
(Fig. 6) (Tuchman et al, 1992). Toe 150 and 360 untranslated 5' and 3' regions are 










Figure 6. Schematic illustration showing synthesis of the OTC protein. (Tuchman et 
al, 1992) 
Toe OTC molecule comprises of two alpha-domains : the carbamyl phosphate (CP) 
binding domain, and the omithine (Om) binding domain. Toe molecule is active as 
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a homo-trimer with the active sites formed at the interfaces between the three 
monomers. This is clearly shown in the ribbon diagram of the OTC model as 
derived from recent X-ray crystallographic studies (Shi et al 2001). 
ORN domain 
SMGloop 
Fig 7. The ribbon diagrams of the OTC homotrimer complex, with each of the 
monomers represented by a different colour. The CP binding pocket is shown at the 
base of the cleft while the Ornithine binding pocket appears on the edge. The 
abbreviation SMG is not clarified in the text. 
The OTC gene is expressed mainly in the liver and intestinal mucosa, whereas other 
tissues show trace or no enzymatic activity. The maximal specific activity of OTC 
in adult human liver is approximately 1 OOµmol citrulline/gm-wet weight per minute 
in liver, whereas the specific enzymatic activity in intestinal tissue is about 20% of 
that found in liver. Problems may be encountered in the enzymatic diagnosis of this 
disorder in newborns and in patients receiving low-protein diets as OTC activity is 
low (Tuchman et al, 1992). 
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1.3.2 Mutation database 
The OTC mutation database (last updated 2001) (URL 7) lists 230 known mutations 
in the OTC gene which result in complete or partial OTC deficiency. The majority of 
mutations found in OTC deficiency, are point mutations. The bulk of these comprise 
missense mutations, followed by nonsense and splice site mutations. Gross 
rearrangements, mainly resulting in partial deletions of the gene, account for 10 
percent of these cases. The least common mutations are large deletions of the whole 
gene and contiguous regions of the X-chromosome. Mutations can be found 
throughout the gene, and almost every family has a unique alteration. The majority 
of males with neonatal onset of OTC deficiency have mutations in the coding region 
of the gene or in adjacent splice sites. Direct mutation analysis is less likely to detect 
mutations in males or females with biochemical studies suggestive of partial OTC 
deficiency because mutations in this category often lie outside the coding region of 
the gene (e.g. cryptic splice sites in introns or mutations in regulatory regions) or in a 
gene other than OTC. (Bale, A. E., 1999) 
Approximately 10% of all point mutations involve the CpG dinucleotide of codon 
141 with a CGA-->CAA transition producing a deleterious Arg-->Gln substitution in 
position 109 of the mature enzyme and causing the elimination of a Taql recognition 
site. The majorities of the remaining mutations in the OTC gene are unique to the 
affected families and are usually not found in unrelated patients. To date, two 
mutations have been described in the sequence of the "leader" peptide, 140 
mutations have been found in the coding sequence of the "mature" enzyme, and 23 
mutations have been discovered in splicing recognition sites. Approximately 20 
single base polymorphisms have been postulated to exist by comparing two reported 
OTC gene sequences; six of these substitutions cause amino acid changes three of 
which have been confirmed in patients (McCullough, B.A, et al. 2000). These 
collective data can serve for genetic counseling and monitoring in prenatal care. 
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1.4 Development and Overview of Thesis 
OTC deficiency is the most common of the urea cycle defects and is encountered 
fairly frequently in the Western Cape. The wide experience of the core laboratories at 
Red Cross Children's Hospital in molecular biology, allowed for several DNA based 
methods to be applied to mutation analysis in the OTC gene. These included PCR, 
SSCP analysis, Southern blotting, hybridisation, RFLP and microsatellite analysis. 
Protocols were optimised for each of these methods and now form part of the 
diagnostic workup for OTC deficiency in Pathology at Red Cross Children's and 
Groote Schuur Hospitals. 
In total, this study examined four patients with OTC deficiency, which was from four 
unrelated families. The initial genetic change in kindred I proved to be a known 
polymorphism in the fourth exon of the OTC gene, comprising a single base 
alteration. Further analysis revealed a novel mutation in the same exon, converting a 
leucine (CTG) to a glutamine (CAG). 
The only sequence alteration detected in patient 2 proved to be a polymorphism 
comprising a single base change in the second exon of the OTC gene. This point 
mutation is listed as a polymorphism in the OTC mutation database and is reported at 
a frequency of less than 10% in a population of European ancestry. The remaining 
OTC exons from this patient were sequenced but no other sequence alteration was 
detected. 
The genetic defect in kindred 3 proved to be a novel mutation, comprising a large 
intragenic deletion, which has removed exons 5 to l 0. This mutation has not been 
listed in the international OTC database and is thus novel. 
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Patient 4 presented with all the features of late onset OTC deficiency, however it was 
also found that the patient had Klinefelter's syndrome, which significantly 
complicated the diagnostic workup. Carrier females for OTC deficiency can present 
clinically, and this is always due to skewed X-inactivation in the liver, where the 
majority ofhepatocytes have the normal X-chromosome inactivated. Skewing of X-
inactivation was thus also a possibility in our patient, as Klinefelter's patients have all 
but one of their X-chromosomes inactivated. There was however a second possibility 
in our patient and that was the inheritance of two copies of the mutant X-
chromosome. Both these possibilities were explored by PCR and microsatellite 
analysis. We were unable to look for skewing in the liver but were able to show 
random X-inactivation in white cells; this finding does not however rule out skewing 
in his liver as the two can be discordant. It was also clear from the microsatellite 
analysis that the patient inherited two different copies of the X-chromosome, which 
would thus require skewing in the liver for the presentation of OTC deficiency. A 
further complicating factor was the finding of normal coding and splice site sequence 
for each of the IO OTC exons. 
An addition to this thesis was the analysis of flanking microsatellite markers for the 
OTC gene; three microsatellites (DXS8090, DXS1068 and DXS8113) were selected 
for analysis. This was prompted by two requests from the parents of the patient in 
kindred 3 for prenatal diagnosis in subsequent pregnancies. All the microsatellites 
gave readable gels after PCR and PAGE. Only one however, proved to be 
informative in this kindred in spite of high reported heterozygosity indexes. This 
microsatellite was successfully used to detect an affected male fetus in the first 
prenatal diagnosis and a carrier female in the second pregnancy. The lack of 
informativeness of two of the three microsatellites in patient 3 was unexpected as the 
reported heterozygosity indexes in the literature are all >0.68. 
The microsatellite markers used in this study have been found to be useful in the 
indirect analysis of the OTC gene and will aid in the pursuit of carrier detection and 
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prenatal diagnosis. It was decided to determine the heterozygosity indexes of these 
three markers in three different population groups in South Africa as these data would 
allow for a ranking of the microsatellites in order of increasing likelihood of being 
informative in future OTC diagnostic interventions. 
In summary, this study has established an experimental approach to DNA based 
diagnosis of OTC deficiency and has filled an important void in the diagnostic 
capability of South African laboratories. Also, no institution in this country has set 
up the OTC enzyme assays, using liver biopsies, normally utilised to confirm OTC 
deficiency. These assays are difficult to establish and maintain, and having an 
alternative diagnostic modality is thus of great benefit. This study has also detected 
two novel mutations, confirmed the presence of two polymorphisms and 
demonstrated as in previous published studies that patients with all the clinical and 
biochemical hallmarks of OTC deficiency, can have a normal coding and splice site 
sequence and presumably carry a mutation in the promotor, or intronic sequences that 
affects the transcription of the enzyme or perhaps even a mutation in some other gene 
impacting on OTC function. 
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CHAPTER2 
2. Mutation Analysis: Kindreds 1-3 (Methods, Results and Conclusion) 
The following format has been used for the presentation of the results. 
2.1 Overview 
2.2 Ethical considerations. 
2.3 Keys to symbols used. 
2.4 Pedigrees of kindreds 1, 2, and 3 together with their clinical, sequencing 
and gene mutation data. 
2.5 Methodology used in the protocols. 
2.6 Results section includes photographs of informative gels with 
explanations, schematic presentations and figures to explain the nature and 
position of the mutations. 
2. 7 Discussion and Conclusion. 
2.1 Overview 
This chapter details the procedures and results of a search for mutations in the 
OTC gene in three unrelated families with phenotypically affected boys and 
pedigree structures strongly suggestive of an X-linked urea cycle defect. This 
study was carried out on banked DNA samples as all families had presented 
during the past 10 years to either of the Red Cross Children's or Groote Schuur 
Hospitals. Banked cultures of fibroblasts and transformed lymphocytes were also 
available as another source of DNA. Identification of mutations in families with 
OTC deficiency enables one to define not only the molecular heterogeneity but 
also helps to expand knowledge of genotype phenotype relationships. In order to 
analyse the entire coding region of each mutant OTC gene, the nucleotide 
sequences, containing each exon plus adjacent intron sequences, were amplified 
by PCR. The sequences of primers were derived from intron sequences close to 
the start and end of each exon. This was done in order to reduce the length of 
flanking intronic sequence co-amplified with the exon, and thus minimise the 
possibility of finding intronic polymorphisms. The details of the PCR reactions 
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and the sequences of the primers have been given in the methods and appendix 
sections. 
SSCP analysis of PCR amplified coding sequences is usually the first line 
approach in the detection of mutations in genes. This is due to the relative 
simplicity of the technique, its sensitivity, rapidity, and cost effectiveness, all of 
which render it a popular screening technique. This technique is capable of 
identifying approximately 80-90% of mutations based on studies of other genes. 
It is generally accepted that mutations that go undetected often lie close to the 
ends of the amplified product. 
SSCP exploits the fact that the electrophoretic mobility of single-stranded DNA 
(ssDNA) during nondenaturing polyacrylamide gel electrophoresis (PAGE) is 
dependent not only on the size, but also on the secondary structure ( conformation) 
of the ssDNA. This secondary structure is stabilised by intrastrand nucleotide 
interactions, which are determined by the base sequence of the strand. Hence, 
any base alteration can potentially affect the strand's conformation and therefore 
it's mobility through and position in the gel. Depending on the resolving power 
of the PAGE system used and the size of the DNA fragment, a single base 
substitution can be detected as a conformation dependant shift in position on the 
gel of one or both of the complementary DNA strands. The mobility shift is 
conformation dependent and while it signals a sequence alteration it has little 
comment on the precise nature of the base substitution. 
Exons showing abnormal migration patterns on SSCP gels were sequenced on an 
ABI sequencer using a cycle sequencing approach and fluorescent labelled 
nucleotides. The fluorescence detectors used are computer controlled and hence 
the data acquisition is automated. 
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2.2 Ethical considerations 
Informed consent is a fundamental requisite in initiating a research project. This is 
usually accomplished by a form given to the participant describing the various 
aspects of the research, manifesting itself as a tool for stimulating a dialogue 
between researches and the potential participants. The research must project into 
the future and anticipate the progress of the research, the possible results it may 
yield, and the ensuing consequences for participants. Specifically the 
development of new knowledge obtained from the relation between the participant 
and public should be fully explored. It is therefore important that the consent 
process include forms that adequately address these issues (Fuller B.P. et al, 
1999). 
There are important factors that should be considered before initiating a research 
project and these factors are listed below. 
a) Ethics approval: The Research Ethics Board will perform a thorough 
evaluation of the project to ensure that the project respect minimal ethical 
standards. The guidelines of the project should be both scientifically and ethically 
acceptable. 
b) Storage of DNA samples: Sample identification is an important factor to 
consider. Human tissue samples must be identifiable, traceable, anonymized and 
be stored for a defined term. Some researchers store samples for five years, 
whereas others prefer twenty five years to allow another generation to potentially 
benefit from the information. When initial consent is taken, the group should 
perhaps include a policy of possibly using the genetic material in other research. 
The participant does not necessarily have to consent to the subsequent research. 
c) Benefits: Consent forms should clearly state any anticipated benefits and the 
participants should not be misled concerning the benefits for themselves. 
Research should not be offered to any participants, if there is no diagnostic test or 
any clinical or scientific validation of the research finding that may have an 
impact on the health of the participant. Some research may not offer any health 
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benefits to the participants, for example, a genotyping project, or projects that 
seek to locate a specific gene. 
d) Risks: Generally there are very few physical risks encountered when 
participating in basic research, for example, the procedure used to draw the DNA 
sample when genetic information is collected, there is a risk that this information 
may be revealed to a third party. This can happen with or without the consent of 
the participant and may lead to discrimination. The participant must be advised of 
this possibility. 
e) Confidentiality: Genetic information acquired about a person over the course 
of research, requires strict confidentiality. Findings of some genetic research may 
provide information, not only about the participant's health, but also their families 
and future progeny. 
f) Communication of results: When results are being communicated to the 
participants, it demonstrates the research group 's appreciation. It also offers 
information about the progress of the work as well as personal results. 
g) Genetic Counselling: Genetic counselling plays a key role in transmitting 
research results. There are various risks, both economical and social risks 
associated with the disclosure of results. When these results have impact on the 
health of the participant, counselling can be psychologically trying for the 
participant and the family and may alter the participants' decisions regarding 
future plans. It is therefore essential that the participant understand the 
implications of the genetic information given. For example, although it may be 
obvious for the research team, that when a person is a carrier of a gene linked to a 
disease, it does not mean that the person will develop the disease. (Deschenes M 
et al, 2001 ). 
This section of ethical issues surrounding consent and DNA banking reveals that 
many of the ethical and legal controversies of genetic research remain unresolved. 
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It is therefore imperative not only to seek possible harmonisation of approaches to 
DNA sampling and banking for research, but also to respect the rights of the 
participants. This respect is a crucial element for creating a climate conductive 
both to protection of research participants and to progress in the field of human 
genetics. Included in this thesis is a copy of the consent form used for the study. 
2.3 Keys to Symbols used in family trees. 
Q D Normal female, male 
e11 Affected female, male 
Deceased, affected female, male 
® Carrier female 
Family member of unknown gender 
Pro band 
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2.4.1 Kindred 1 
Patient 1 (11.5), the second son of healthy parents and brother of a healthy sister 
and deceased, affected brother (Fig 8) developed fatal hyperammonemia during 
the frrst few days of life. The family history was significant in the context of X-
linked inheritance as the mother had lost two sons in the neonatal period, one 
from previous marriage. Patient 1 died twenty days after birth. 
I 
3 1 2 
II • 
2 3 4 5" Patient 1 
Figure 8. The pedigree of kindred 1 showing the affected male proband, a 
deceased male sibling and a phenotypically normal sister. Also shown are a 
deceased half brother and phenotypically normal half sister. For completeness, 
the genotype findings in this study have also been included in this pedigree. 
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2.4.2 Kindred 2 
Patient 2, (Il.5) was the fifth son born of healthy parents, and brother of four 
deceased, boys (Fig 9). He was originally diagnosed as having CPS deficiency, 
but the family pedigree strongly indicated an X-linked pattern of inheritance and a 
likely OTC defect. An amino acid analysis of plasma specimens confirmed the 
absence of citrulline, more important there was an increase of orotic acid 




2 3 4 s\ 
Patient 2 
Figure 9. The family tree of kindred 2. Shown are the parents, the proband and 4 
deceased male siblings. For completeness, the genotype findings in this study 
have also been included in this pedigree. 
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2.4.3 Kindred 3 
Patient 3 (II.4 ), the fourth son of healthy parents and brother of two deceased, 
affected siblings and one normal brother (Fig 10), developed fatal 
hyperammonemia a month after birth, and died in early infancy. Urinary orotic 
acid levels were considerably elevated in this neonate. This finding, coupled with 
the family history of multiple early male deaths was strongly suggestive of an X-




2 3 4 
' Patient3 
Figure 10. The family tree of patient 3 (Il.4) showing two affected male siblings. 
one normal male sibling and both parents. An arrow indicates the proband. For 
completeness, the genotype findings in this study have also been included in this 
pedigree. 
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Chapter 2.5: Methodology 
The major steps followed in the mutation analysis of the OTC gene are given in 
the following flow diagram. Please refer to appendix for details concerning the 
reagents. 
Flow diagram of the study protocol 
I. Blood from Patient 
2. Transformed fibroblasts 
3. Skin fibroblasts 
Single Stranded Conformational 






PCR of OTC gene (IO exons) 
l 
Southern Blotting in case of deletions 
l 
Hybridisation using the OTC cDNA 
Mutational analysis using automated sequencing results 
Figure 11. Flow diagram representing the methodology used in the mutational 
analysis of the OTC gene. 
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The DNA extraction method of Parzer et al 1991 was found to be optimal for 
heparinized blood and the non-enzymatic salt method of Lahiri et al 1991 was 
optimal for EDTA blood. All the DNA samples were observed to be intact and of 
high molecular weight on electrophoretic analysis. 
2.5.1. 
2.5.1.1. 
Genomic DNA extraction protocols 
Whole blood extraction method 
Whole blood was collected in a Vacutainer tube containing 100 µI of 15% EDT A 
(1 mg/ml). Blood (5 ml) was transferred into a 15 ml centrifuge tube containing 5 
ml of low salt buffer. Nonidet P-40 (125 µI) (NP-40, Sigma) was added and the 
tubes were mixed well by several inversions to lyse the cells. Samples were then 
centrifuged for 10 minutes at 2200 RPM at room temp. (Beckman centrifuge). 
Supernatant was decanted and the nuclear pellet (the small pellet at the very 
bottom of the tube) was washed in 5 ml of TKMl buffer. Samples were 
centrifuged as before. The pellet was gently resuspended in 0.8 ml of high salt 
buffer and 50 µl of 10% SDS. The whole suspension was mixed thoroughly by 
pipetting back and forth several times, incubated at 55°C for 10 minutes. To the 
tubes 0.30 ml of 6 M NaCl was added and mixed well. Samples were centrifuge 
for 5 min at 12000RPM, in a microcentrifuge. The supernatant containing the 
DNA was saved and the precipitated protein pellet at the bottom of the tube was 
discarded. To the supernatant 2 volumes of 100% ethanol was added at room 
temperature. The tubes were inverted several times to precipitate the DNA in the 
solution. Precipitated DNA strands were put in a microfuge tube containing 1 ml 
of ice-cold 70% ethanol and microfuged for 5 min at 12000RPM at 4 °C. Pellet 
was dried in a Speed-vac and the DNA was resuspended in 0.5 ml of TE buffer 
and incubated at 65°C for 15 min to allow for complete dissolution. 
2.5.1.2. Frozen blood extraction method 
Frozen blood (5 ml) was thawed at 37°C and mixed with 50 ml of cell lysis buffer 
(blood: lysis buffer ratio of 1 :5) in a Beckman tube and incubated for 15 min. on 
ice. Samples were centrifuge for 10 min. at 6800g and 4 °C and the supernatant 
was immediately decanted. The pellet was resuspended in 50 ml of wash buffer 
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and centrifuge for 10 mm. at 6300g and 4°C. Again the supernatant was 
immediately decanted. The remaining pellet (which should be almost white) was 
mixed with the following reagents in this order: 350 µI of 20% sodium sarkosyl, 
250 µI of 7.5 M-ammonium acetate, 3.5 ml of 6 M-guanidinium chloride and 125 
µI of proteinase K (1 Omg/ml). Beckman tubes were incubated for 15 minutes at 
60°C or until the solution was clear and immediately cooled to 0°C. DNA was 
precipitated by the addition of 10 ml ice-cold ethanol. Gelatinous DNA was 
spooled on a hooked glass rod and released into 500 µI of TE buffer and allowed 
to dissolve completely in the tube by incubating it for I hour at 37°C or overnight 
at room temperature. 
Generally under these conditions the DNA is not completely soluble. However the 
insoluble material can easily be separated and removed by centrifugation ( 10-15 
s) at lOOOg in a Microfuge centrifuge. 
The concentration and purity of the DNA was determined by measuring the 
OD260/0D2so ratio and by viewing the extracted DNA on agarose gel 
electrophoresis. 
2.5.1.3. Bloodspot extraction method 
Whole blood (250µ1; EDT A or heparinized) was pipetted onto sterile filter paper, 
allowed to dry overnight, sealed in a plastic sleeve and stored at -20°C for future 
studies. 
A 3mm x 4mm square of the bloodspot was cut out with a sterile blade and 
dropped into a 1.5 ml Eppendorf. Methanol was added to the tube to cover the 
square and was left to stand for 5 minutes and then allowed to dry completely. 
Boiling each piece in 50 µl sterile water for 15 minutes liberated the DNA. The 
mixture was then centrifuged for 10 minutes at 10 OOOrpm's and kept on ice. On 
average l 0-20 µl of the extract was used for PCR reactions with a final volume of 
50 µI. 
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2.5.2. Determination of DNA concentration 
2.5.2.1. By Spectrophotometric readings A260 
A 1 : 100 dilution of DNA was prepared in distilled water ( 10 µl in 990 µl) and the 
absorbance readings taken at OD26o and OD2so on a spectrophotometer. The 
A260/A2so 
ratio gives an indication of the purity of the DNA preparation. A pure sample 
would have a ratio of 1.8 - 2.0. 
The DNA concentrations were calculated as follows: 
For double stranded DNA 1 OD= 50 µg/ml 
For single stranded DNA 1 OD = 33 µg/ml 
DNA concentration= OD260 x 50 µglml (or 33 µglml) x dilution factor 
2.5.2.2. By agarose gel electrophoresis 
A 1 µl DNA sample was mixed with 3 µl of 6 x loading buffer and the sample 
made up to 10 µl with distilled water. This was run on a 0.8% agarose gel in 1 x 
T AE buffer at a constant voltage of 80Volts/cm for 30 minutes. A high molecular 
weight marker was run on the gel for comparison to the genomic DNA. 
Ethidium bromide is a florescent dye that intercalates between the DNA strands, 
allowing visualization of the product under a UV transilluminator. Smearing 
would indicate degradation of the DNA. Quantitation of the DNA can be 
achieved by comparing the intensities of the bands of the different genomic DNA 
or PCR samples to the intensity of DNA bands of concentration. 
2.5.3. Polymerase Chain Reaction (PCR) 
2.5.3.1. Primer design 
All primers were designed using the OLIGO ™ computer program. Here sequence 
length, GC content, melting temperatures and oligo self-complimentarity were 
easily compared. 
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2.5.3.2. PCR amplification 
The following quantities were used per reaction mix in a 50 µl sample tube: 4 µI 
2.5mM dNTP's, 4.5 µl 10 x Promega buffer, 2.0 µl 25mM MgCh, 1.0 µl 20pM 
forward primer, 1.0 µl 20pM reverse primer, 31.5 µl distilled water and 1.0 µl 
0.5 µg/µl DNA. Control samples with no DNA were added as well. PCR 
mixtures were overlaid with mineral oil ( 45 µl) to prevent evaporation and 
condensation of the samples. Tubes were placed in a thermocycler and subjected 
to a "hot start" by the addition of the 5 µl enzyme mix after the first 95°C for 3 
minutes step in the PCR cycle. An enzyme mix was prepared to contain the 
following quantities per reaction: 0.5 µl Taq DNA polymerase (5U/µl) , 0.5 µl 10 
x Promega buffer, 4.0 µl distilled water. 
2.5.3.3. Thermocycling 
An appropriate annealing temperature profiles was chosen for each set of primers 
and the individual annealing temperatures were programmed into the 
thermocycler (Appendix). 
The following template programme was used: 
Step 1. Denaturation at 95°C for 3 minutes 
This was set for 1 cycle 
11. denaturation at 95°C for 30 seconds 
lll. annealing at _ °C for 1 minute 
1v. extension at 72°C for I minute 
This was repeated for 10 cycles 
v. denaturation at 92°C for 30 seconds 
VI. annealing at _°C for 1 minute 
v11. extension at 72°C for 1 minute 
This was repeated for 23 cycles 
v11. Final extension at 72°C for 5 minutes 
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2.5.3.4. Agarose gel electrophoresis 
An aliquot (5 µl) PCR product was mixed with 2 µl of 6 x loading dye and 
electrophoresed on a 2.0% agarose gel in 1 x T AE buffer at a constant voltage of 
1 OOVolts/cm for 45 minutes. A high molecular weight marker was prepared and 
run on the gel for size determination of the PCR product. 
2.5.4. 
2.5.4.1. 
Single stranded conformation polymorphism (SSCP) 
Preparation of plates 
The surfaces of both plates were thoroughly washed with detergent and 70% 
ethanol and allowed to dry completely. Siliconizing agent was applied (in a fume 
cupboard) to one plate and vigorously rubbed onto the surface. The plate was 
allowed to stand in the fume cupboard for a few minutes. A plate glue mix, 
containing 90 µl 10% acetic acid and 3 ml of the plate glue stock, was thoroughly 
rubbed onto the surface of the other plate which was allowed to stand for 3 
minutes. Excess plate glue was rubbed off with 100% ethanol. The ethanol wipe 
was done twice to ensure the removal of the plate glue, to prevent the plates 
sticking together after electrophoresis, due to the diffusion of the glue through the 
gel. The plates were assembled and secured with the aid of bulldog clips and with 
spacers (0.4 mm) separating the two plates. 
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2.5.4.2. Preparation of polyacrylamide (PAGE) gels 
2.5.4.2.1. Gel type 1 2.5.4.2.2. Gel type 2 
The following volumes were added to The following volumes were added to 
make gel type 1 : make gel type 2: 
40% Acrylamide stock (39.6:0.4) 18.75ml I 0% Acrylamide (30:0.8) 27ml 
0.6 x TBE 9ml 5 xTBE 8ml 
Pure Urea 5.6 g glycerol 4ml 
10% APS (Ammonium Persulfate) 400 µI 10%Urea 12 g 
Distilled water 40ml distilled water 35 ml 
TEMED 25 µI 10%APS 800 µI 
TEMED 80 µI 
Total -70 ml Total -75ml 
TEMED was added last as this caused polymerisation of the gel mix. The solution 
was gently mixed, taken up in a 50 ml syringe and poured between the two plates 
which were lying on a flat surface. A well-forming comb was inserted at the top 
of the two plates and bulldog clamps were used to hold the two plates firmly 
together until polymerisation was completed. This process occurred in about 90 
minutes. The gels were then ready for use. 
2.5.4.3. Sample preparation and electrophoresis 
An aliquot (5 µl) of the PCR product was mixed with SSCP loading dye (5 µl). 
Tubes were incubated at 95°C for 3 minutes to denature the DNA and 
immediately put on ice. Combs were removed from the gel to form the wells. 
The gel was placed into the electrophoresis tank and filled with TBE buffer. The 
wells were cleaned of urea with the aid of a syringe. Two different gel conditions 
were followed. Gel type 1 was run at room temperature at 6W overnight. Gel 
type 2 was run in the cold room, which was at 4°C, overnight. Gel type 2 had an 
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The silver stain relies on the change in pH and the precipitation reaction of the 
silver ions onto the DNA in the gels. Ammonia was used for gel impregnation 
and a dilute acid solution of formalin was used for image development, which was 
brought about by the change in pH from basic to acidic which caused the silver 
ions to deposit onto the DNA thereby forming insoluble silver salts. 
The two plates were disassembled and the plate containing the gel was put in a gel 
tray for silver staining. This plate was covered with 2 litres of distilled water and 
gently agitated for 30 minutes following which water was discarded and the 
ammoniacal silver solution was added. The tray was covered to limit evaporation 
and slowly agitated for 20 minutes. The silver solution was poured off. Distilled 
water was added to the tray to cover the gel and left to shake for 30 seconds. 
Water was discarded and the developing solution ( citric acid, formalin) added to 
the tray. The reaction was stopped when faint bands became visible on the gel. 
The developing solution was discarded and water was added to the tray. When the 
bands were clearly visible a photo of the gel was taken and the plates soaked in 
0.5M NaOH to remove the gel from the plate following which the plates were 
given a quick rinse and stored for the next gel. 
The high sensitivity of the silver stain technique renders it susceptible to staining 
artefacts and impurities. The use of deionised water is critical for the success of 
the procedure and the conductivity of the distilled water should be measured 
before use. 
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2.5.5.2. Method 2 
Following electrophoresis and disassembly the plate containing the gel was put in 
a gel tray for silver staining. The gel was then covered with 2 litres of distilled 
water and gently agitated for 1 minute. The water was then discarded and 
solution! was added. The tray was slowly agitated for 10-15 minutes. Solution 1 
(AgN03) was decanted and distilled water was poured into the tray and left to 
shake for 2 minutes. The water was then discarded and the second solution was 
then added to the tray. Agitation was continued for 10-15 minutes or until the 
bands were clearly visible. Solution 2 (NaOH I NaBH4 and formaldehyde) was 
then discarded and water was added to the tray and left to agitate for 1 minute. 
Thereafter the water was discarded and solution 3 was added to the tray to sharpen 
the bands. Solution 3 (Na2C03) was then discarded and the gel was then 
reimrnersed in water. The gel was then viewed under a light box. A photograph 
of the gel was taken and the plates were soaked in 0.5M NaOH to remove the gel 
from the plate. The plates were given a quick rinse and then stored for the next 
gel. 
The exons showing a band shift were then amplified through PCR, purified and 




Purification of DNA 
2.5.6.1.1. Ammonium acetate precipitation 
To the PCR product 1/2 volume of cold 7.5M ammonium acetate was added and 
the tubes mixed. Cold absolute ethanol (2.5 volumes) was added and mixed. The 
tubes were then placed at -70°C for 30 minutes to precipitate DNA. This was 
recovered by centrifugation for 20 minutes in microfuge at 14000rpm's. The 
supernatant was discarded and the pellet washed with 70% cold ethanol and 
centrifuged for 10 minutes at 14000rpm's. The supernatant was discarded and the 
pellet allowed to dry for 5 minutes in a speedvac. The DNA pellet was then 
dissolved in 50 µl TE or distilled water. 
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2.5.6.1.2. By agarose gel electrophoresis 
The 50 µl of DNA was then mixed with 6 µl 40%sucrose and pipetted into the 
wells of the 1 % low melting point agarose gel and electrophoresed in 1 x T AE 
buffer at a constant voltage of 60V for 45 minutes. An appropriate molecular 
weight marker was run to be able to track the migration of the bands in the gel. 
Ethidium bromide was not used to stain the DNA. The separated bands were 
viewed under the UV transilluminator and the appropriate bands were cut out with 
a sterile blade, cutting as little of the agarose around the band as possible. The 
excised bands were then weighed and dropped into a 1.5 ml Eppendorf. 
2.5.6.1.3. Qiagen II gel extraction kit 
The bands were then purified with the aid of the Qiagen II Gel Extraction Kit. A 
volume of 0.3 ml QXI solubilization buffer was added per 100 mg of gel. After 
solubilization 10 µl of Qiaex beads was added to the Eppendorf and the 
suspension was then incubated at 50°C for 10 minutes, with vortexing at 2 minute 
intervals. The samples were then centrifuged in a microfuge for 30 seconds. 
Supernatant was carefully removed and the pellet in 0.5 ml QXI buffer to get rid 
of residual agarose. The pellet was then resuspended in 0.5 ml equilibration 
buffer PE, washed twice to the remove the salt contaminants and air dried for 15 
minutes until it became white. DNA was eluted from the beads by the addition of 
20 µl TE buffer, vortexing, incubation at room temperature for 5 minutes, which 
was then followed by centrifugation for 30 seconds. The supernatant, now 
containing the DNA, was carefully removed. This elution process was repeated 
twice. The purity and concentration of the DNA was determined through 
spectrophotometric readings and 0.8% agarose gel electrophoresis. 
2.5.6.2. Automated Sequencing 
For the sequencing of PCR DNA template a concentration of 180-250 ng was 
required per reaction. The template (250 ng) and the primer (20 pM/µl per 
reaction) were supplied in a single tube, which was made up to a total volume of 
12 µl with distilled water for each primer. 
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Sequencing was done on an ABI 3 73 stretch automated sequencer using 4-colour 
fluorescent technology. Cycle sequencing using dye-labelled terminators was 
used. It is a rapid and convenient method of performing enzymatic extension 
reactions for DNA sequencing. The enzyme used was Amplitaq DNA polymerase 
FS that was developed specifically for fluorescent cycle sequencing. It is a mutant 
form of Taq DNA polymerase which has essentially no 5'-3' exonuclease activity 
and has a drastically reduced discrimination for dideoxynucleotides. Essentially 
the symmetric double-stranded PCR templates were purified prior to sequencing 
and then subject to 25 rounds of cycle sequencing reaction with sequencing 
primers and terminator premix (A-dye, C-Dye, G-dye, T-Dye, dGTP, dATP, 
dCTP, dTTP Tris-HCl pH 9.0, MgC12, thermostable pyrophosphatase and 
Amplitaq FS) followed by ethanol precipitation to remove unincorporated 
nucleotides. The samples were resuspended in formamide, denatured and loaded 
onto an 4.25% polyacrylamide (Ameresco) gel and electrophoresed for 16 h at 
1000 v, 32 watts. Automated analysis was performed using ABI sequencing 
analysis software version 2.0.12.0.1. 
2.5.6.3. Restriction digestion 
2.5.6.3.1. Primer design 
Often a mutation can be verified with the aid of restriction enzymes as the 
sequence alteration in the DNA destroys or creates a cutting site for one of these 
enzymes. 
The mutation detected in patient 2 destroyed a restriction site in the PCR product 
from the mutant allele. 
2.5.6.3.2. PCR product amplification 
The PCR amplification protocol was followed as in 2.5.3.1. - 2.5.3.4. 
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2.5.6.3.3. PCR product digestion 
Dde I (1OU/µl)-10 x Buffer H incubated at 37°C (refer to Fig 19) 
The restriction digest contained the following quantities per 20 µI sample: 
PCR product 5 µl 
10 x Buffer 2 µI 
Enzyme (10 U/µl) 2 µI 
distilled water 11 µl 
20 µI 
The undigested samples were used as controls and contained no enzyme but 
instead contained equal volumes of distilled water as replacement. The PCR 
products were incubated with the enzyme and buffer combination at 3 7°C. 
Digestion was allowed to occur overnight and the products were run on a 20% 
PAGE gel. 
2.5.6.3.4. Electrophoresis and visualisation 
The following gel mix for a 20% PAGE gel was added to an Erlenmeyer flask: 
30% acrylamide (29:1) 33.3ml 
5 xTBE lOrnl 
distilled water 6.3 ml 
10%APS 400 µl 
TE MED 25 µl 
50 ml 
Two small plates (15 cm x 15 cm) were a cleaned and assembled. Two spacers of 
sizes 0.75 mm were used to separate the plates. A 0.75 mm comb was used to 
form the wells. After polymerisation the comb was removed and the gel was 
placed in the tank in 1 x TBE buffer. 
l Oµl of digested product was mixed with 2 µl of 6 x loading dye and loaded into 
the wells. The gel was electrophoresed at 220V for 3 hours. The products were 
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visualised with the aid of a silver stain or an ethidium bromide stain (9 µl EtBr 
mixed with 125 ml 5 x TBE). 
2.5.7. RFLP and Southern Blot Analysis 
2.5. 7.1. Digestion of Genomic DNA 
A 10 µg amount of each sample (Patient DNA and Control DNA) of genomic 
DNA was incubated with 4 µl (BamHI, Hind/II, and Pvull) restriction enzyme and 
10 µl 1 OX Incubation buffer in a total volume of 100 µl ddH20 at 3 7°C overnight. 
2.5. 7.2 Precipitation of Digested Product 
Cold absolute ethanol (2.5 volume 100%) was added to the Restriction digested 
product and mixed. The tubes were then placed at -70°C for 30 minutes to 
precipitate DNA. The tubes were then centrifuged for 20 minutes in microfuge at 
14000rpm's. The supernatant was then discarded and the pellet was washed with 
70% cold ethanol and centrifuged for 10 minutes at 14000rpm's. The supernatant 
was discarded and the pellet was allowed to dry for 5 minutes in a speedvac (An 
instrument used to dry specimens using liquid N2• The DNA pellet was then 
resuspended in 15 µl distilled water to dissolve. 
2.5. 7.3. Gel Electrophoresis of Digested Product 
The digested DNA samples were electrophoresed in IX TAE buffer, at 30V for 16 
hours(overnight) on a large 0.8% agarose gel in 150 ml of IX TAE containing 2ul 
10 mg/ml ethidium bromide. A high molecular weight maker was run on the gel 
for comparison of the digested bands. Ethidium bromide staining allowed the 
DNA to be visualised using a UV transilluminator. A photograph of the gel 
alongside a ruler was taken, under UV light, for reference, allowing for 
calculation of molecular weights of individual bands ultimately observed on the 
autoradiograph, according to the distance travelled on the gel. 
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2.5. 7.4. Transfer of DNA onto nylon membrane. 
Gloves were worn as protection against acidic and alkaline solutions and to 
prevent membrane contamination. The gel was removed from the tray and placed 
in a glass dish. Ten gel volumes of 0.25M HCl (approximately 1.5 L) were added 
to the glass dish, which was incubated on a platform shaker for 30 minutes at 
room temperature. This step results in partial depurination of the DNA fragments, 
which lead to strand cleavage. The length reduction improves the transfer on 
longer molecules. 
(Depurination was stopped after 10 minutes when the xylene cyanol and 
bromophenol blue dyes, have changed to green and yellow respectively). The 
HCl was poured off and the gel was rinsed with distilled water. Ten gel volumes 
of 0.4 M NaOH was added to the gel in the glass dish, and was incubated as 
previously described. This was the denaturation step. 
A clean piece of plastic wrap was placed on the bench top. A clean glass plate 
was placed in the centre of the plastic wrap. Once the gel has been washed in 
0.25 M HCl and 0.4 M NaOH, it was carefully transferred onto the glass plate. 
The edges of the plastic wrap were folded up to cover all four outer edges of the 
gel. Care was taken to ensure that edges were not exposed and that the plastic did 
not cover the outer lanes. The Hybond membrane was cut to the size of the gel, 
and wet in 0.4 M NaOH. It was then laid over the gel and the bubbles gently 
pressed out. Care was taken to handle the membrane with gloves and forceps to 
avoid contamination by fingerprints. The top right-hand comer was cut for 
orientation. Three pieces of similar size filter paper that have been soaked in 0.4 
M NaOH were placed on top of the membrane. A 2" stack of folded paper towel 
was placed on top of the filter papers. A weight (Perspex tray and a bottle) was 
placed on top of the paper towel. This apparatus was left at room temperature for 
approximately 16 hours overnight, for the transfer of the DNA onto the membrane 
to occur by trans gel buffer flow. 
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2.5.8. Preparation of cDNA Probe 
(The cDNA was used as a probe for the hybridization step) 
2.5.8.1. Preparation of cDNA clone 
Dr. Wayne Fenton, Yale University, supplied the clone pH0731 (5-10 µg). 
PH073 l an ethanol precipitate was resuspended in 100 µl sterile TE buffer to 
yield a concentration of 0.05 µg/µl or 50 ng/µl. This was aliquoted into 5 tubes 
and stored at -70°C. For PCR, a 1:1000 dilution was made to yield a 
concentration of 0.05 ng/µl. 
2.5.8.2. PCR of OTC cDNA (pH0731) 
The following OTC primers were used to amplify the whole cDNA: 
OTC Exonl Fonvard: 5' -AGT TTT CAA GGG CAT AGA ATC-3' 
OTC ExonlO Reverse: 5'-TCA TTC TGT TAC TGA AGA ACA TTG C-3 ' 
The PCR amplification protocol was followed as in 2.5.3. These primers used a 
final MgCli concentration of 1.5 mM and an annealing temperature of 55 I 52 °C. 
(See section 2.5.3) 
2.5.8.3. Concentration of pooled PCR product ( cDNA) 
Pooled PCR products of 10 samples were concentrated by adding 1/2 volume of 
cold 7.5 M ammonium acetate were added to the tubes. To this 2.5 volume 100% 
cold absolute ethanol were added, mixed and incubated at -70°C for 30 minutes to 
precipitate DNA. The tubes were then centrifuged for 20-30 minutes in 
microfuge at 14000rpm. The supernatant was then discarded and the pellet was 
washed with 70% cold ethanol and centrifuged for 10 minutes at 14000rpm. The 
supernatant was again discarded and the pellet was allowed to dry for 5 minutes in 
a speedvac and resuspended in 50 µl TE or distilled water to dissolve. 
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2.5.8.4. Agarose Gel Electrophoresis of cDNA Probe 
The 50µ1 of DNA was then mixed with 6 µI 40% sucrose and pipetted into the 
wells of the 1 % low melting point agarose gel. The DNA was electrophoresed in 
1 x TAE buffer at a constant voltage of 60V for 45 minutes. An appropriate 
molecular weight marker was run to be able to track the migration of the bands in 
the gel. The separated bands were viewed under the UV transilluminator and the 
appropriate bands were cut out with a sterile blade, cutting as little of the agarose 
around the band as possible. The excised bands were then weighed and dropped 
into a 1.5 ml Eppendorf. 
2.5.8.5. Qiaex II gel extraction kit 
The bands were then purified with the aid of the Qiaex II Gel Extraction Kit. A 
volume of 0.3 ml QXl solubilization buffer was added per 100 mg of gel. After 
solubilization 10 µI of Qiaex beads was added to the Eppendorf and the 
suspension was then incubated at 50°C for 10 minutes, with vortexing at 2 minute 
intervals. The samples were then centrifuged in a microfuge for 30 seconds. The 
supernatant was then carefully removed and the pellet was then washed in 0.5 ml 
QXl buffer to get rid of residual agarose. The pellet was then resuspended in 0.5 
ml equilibration buffer PE and washed twice to the remove the salt contaminants. 
The pellet was then left to air dry for 15 minutes until it became white. The DNA 
was eluted with the addition of 20 µI TE buffer to the pellet, which was then 
vortexed, incubated at room temperature for 5 minutes and then centrifuged for 30 
seconds. The supernatant, now containing the DNA, was carefully removed. This 
elution process was repeated twice. The purity and concentration of the DNA was 
determined through spectrophotometric readings and 0.8% agarose gel 
electrophoresis. 
2.5.8.6. Labelling of cDNA probe 
The Expand TM Long Template PCR System was used (Boehringer Mannheim, 
Cat No. 1681 842). This kit contained non-radioactive components to be used 
with radiolabelled dATP. Unlabelled dCTP, dGTP, dTTP (supplied with the kit) 
and then 1 µI [ a 32P] dA TP were the nucleotides incorporated during DNA 
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synthesis, achieving efficient incorporation of the label. Two of the OTC primers 
were used to amplify the cDNA. These primers were OTCExlForward and 
OTCExlOReverse at a concentration of 20 pmoles/µ1. 
2.5.8.7. PCR Amplification Protocol. 
All the reagents were thawed and kept on ice. Both primers amplified at a final 
MgCh of l.5mM and an annealing temperature of 55 ° C or 52 °C. 









lOX PCR Buffer 
dNTP' s (C, T, and G) (5 mM) 
OTCExlForward (20 pmoles/µl) 
OTCExlOReverse (20 pmoles/µl) 
ddH20 
MgCh (1.5 mM) 
[a 32P] dATP 
Enzyme Mix per sample 
0.5 µl Enzyme (kit) 
0.5 µl lOX Buffer 
4.0 µl ddH20 
5.0 µl 
4.0 µl Template DNA (OTCcDNA-0.05 ng/µl) 
2.5.8.8. Thermocycling 
Primers, OTC Exonl Forward and OTC ExonlO Reverse, amplified at an 
annealing temperature of 55°C. 
Step 1. Denaturation at 95°C for 3 minutes 
2. "hot start" at 75°C for 1 minute 
This was set for 1 cycle. 
3. Denaturation at 95°C for 30 seconds 
4. Annealing at 55°C for 1 minute 
5. Extension at 72°C for 1 minute 
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This was repeated for 10 cycles. 
6. Denaturation at 92°C for 30 seconds 
7. Annealing at 55°C for 1 minute 
8. Extension at 72°C for 1 minute 
This was repeated for 23 cycles. 
9. Final extension at 72°C for 5 minutes. 
2.5.8.9. Hybridisation 
All incubations took place in a rolling hybridisation cylinder in a hybridisation 
oven. The membrane with the transferred DNA on it was rolled in a piece of 
nylon mesh, which was cut to approximately the same size as the membrane. This 
was then placed in the hybridisation cylinder with 60ml hybridisation buffer and 
incubated at 64°C for approximately 2 hours. Heating it at 95°C for 10 minutes 
denatured the Probe. The hybridisation buffer was poured off and replaced with 
an equal volume of prewarrned Hybridisation buffer, which had the probe, added 
to it. This was incubated at 64°C overnight. Note that preheating of the 
hybridisation buffer is critical for uniform blocking of the membrane, as failure to 
preheat the buffer results in absorption of the DNA probe by the blocking agents. 
Also note that the concentrated probe should not be poured directly onto the 
membrane as localised background may occur. The probe was poured off and 
stored at -20°C for reuse. The membrane was placed in a glass dish and washed 
with 250 ml 2XSSC/0.1 %SOS for 10 minutes at room temperature, changing the 
solution after 5 minutes. Then the membrane was washed with 
0.2XSSC/0.1 %SDS for 10 minutes at room temperature, changing the solution 
after 5 minutes. After the washes, the membrane was wrapped in Saran Wrap and 
checked for excessive radioactivity with the Geiger counter, to ensure that the 
washes had been sufficient. 
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2.5.8.10. Auto radiography 
The membrane was wrapped in Saran Wrap and placed in an X-ray film cassette, 
covered with Hyperfilm MP (Amersham), and exposed at-70°C for 7 days. 
Materials and Reagents: Developer solution 
Stop solution (2% acetic acid) 
Fixer solution 
A 1 :3 dilution was made and the pH and silver content was checked. 
2.5.8.11. Protocol for developing of the autoradiograph 
In the darkroom (using the red light only) the cassette was opened, the autorad 
removed and placed in developer solution for 90 seconds, in stop solution for 30 
seconds and in the fixer solution for 2 minutes. The autoradiograph was then 
placed in running tap water for 5 minutes and left to dry. 
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Chapter 2.6: Results 
SSCP analysis of PCR amplified coding sequences. 
Kindred 1, Patient 1 
SSCP analysis revealed an abnormal migration pattern of ssDNA fragments from 
exon 4 of patient 1 (fig. 12). 
1 2 3 
c c c 
Figure 12. An SSCP gel showing the banding pattern of the single strands from 
the PCR product of exon 4. The bands from patient 1 are depicted on the right 
(lane 4) and preceded by the bands from 3 control individuals (lanes 1-3). 
Exon 4 was sequenced and an A to T transversion found at nucleotide position 
438 of the OTC cDNA (Accession number D00224). This substitution occurred 
in codon 101 of the mature OTC protein and resulted in substitution of 
phenylalanine for leucine. This transversion converts the TT A codon for leucine 
to TIT, which codes for phenylalanine (LlOlF). The sequencing trace and 
summary details are given in figures 13 and 14 respectively. Substitutions at the 
3rd position of codons are usually inconsequential, as this position is degenerate. 
However, several amino acids are determined by the nature of the base in this 
position; phenylalanine and leucine being two of these amino acids. Currently 
there are 13 different mutations reported in exon 4 in the OTC database. LlOlF 
appears in the database and is reported as a polymorphism. 
Another single base substitution was found in codon 104 of the mature OTC 
protein, which results in substitution of glutamine for leucine at nucleotide 
position 446. This transversion converts the CTG codon for leucine to CAG, 
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which codes for glutamine (L 104Q). The sequencing trace and summary details 
are likewise given in figures 13 and 14 respectively. L104Q appears to be a novel 
mutation, as it is not listed in the database. 
Subsequently, maternal DNA from the mother and two female siblings of patient 
1 was amplified and sequenced to screen for the L104Q mutation and LIOIF 
polymorphism. The results revealed that the mother is a carrier for she is 
heterozygous for the L 104Q mutation. One of the female siblings was also found 
to be heterozygous for the L 104Q mutation, making her a carrier as well. The 
other sibling is homozygous for the normal sequence. Both female siblings and 
the mother tested positive for the L 101 F polymorphism. The sequence traces 
showing the base changes mentioned above are given in figure 15. 
A 
Patient 
~ ., G 
33 435 436 437 438 439 440 441442 443 444 445 446 447 
100 101 102 103 104 105 
B IG C T T ~ G C A C T T C ! G G G A I control 
Figure 13. A) A section of the sequence trace from exon 4 of patient 1, 
spanning codons 100 to 105 and showing the two transversions. B) A section of 
the sequence trace from exon 4 of a control spanning codons 100 to 105. 
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Abbreviation: 
Amino acid sequence: 





















G L A L L G 
Gly Leu Ala Leu Leu Gly 
GGC TTA GCA CTT CTG GGA 
GGC TIT GCA CTT CAG GGA 
100 101 102 103 104 105 
LlOIF 
Conservative: nonpolar 7 nonpolar 
T446 __.. A«6 
L104Q 


















Figure 14. A composite of the characteristics and nature of the polymorphism 
and mutation in exon 4 of the OTC gene of patient I. Numbering is taken from 
the DNA sequence lodged in Genbank under accession number D00224. 
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Mother 
(' - (". r . 
433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 
Daughter l G 
. , 
433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 
Ii 
Daughter 2 !!.... >". 
433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 
100 101 102 103 104 105 
Control GGC TTA GCA CTT CTG GGA 
Figure 15. Kindred 1: Sequence traces of the mother (carrier) and her two 
daughters (Daughter 1 - carrier and daughter 2 - normal) showing homozygosity 
for the T polymorphism at nucleotide 438 I codon 101 in all three traces in 
addition to heterozygosity for the A/T mutation at nucleotide 446 I codon 104 in 
the mother and daughter 1. 
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Table 1 Sequence conservation of OTC Exon 4 amongst species 
Species Sequence 
Amino Acid (homo sapiens) Gly leu ala leu leu gly gly his pro 
Codons 100 101 102 103 104 105 106 107 108 
Homo Sapiens (humans) GGC TTA GCA CIT CTG GGA GGA CAT CCT 
Mus musculus (house mouse) GGC ITT GCT CTG CTG GGA GGA CAC CCT 
Bos taurus (cow) GGC TTT GCA CIT CTG GGA GGA CAC CCT 
Rattus norvegicus (Norway rat) GGC TTC GCT CTT CTG GGA GGA CAT CCT 
Rana catesbeiana (bullfrog) GGA TTT GCT TT A TTG GGA GGA CAT CCT 
Trachemvs scri(!ta elegans GGG ITT GCT CTC CTT GGG GGA CAT CCT 
Gallus gallus (chicken) GGA ITT GCT CTC CTT GGA GGA CAT TCT * 
Sus scrofa (pig) GGC TTT GCC CIT CT A GGA GGA CAC CCT 
* Pro ----+ Ser 
Other mutations have been reported in close proximity i.e. at codons 100 (gly to 
asp), 102 ( ala to gl y) and 106 (gl y to arg) suggesting that amino acid sequence 
conservation in this section of the polypeptide chain is critical for enzyme 
function. This is also borne out by the conservation of sequence in different 
species (table 1 ). Only one amino acid change is found in the 9 amino acid 
segment shown in table 1, this being a substitution of pro line by serine in chicken. 
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Kindred 2, Patient 2 
SSCP analysis revealed an abnormal migration pattern of ssDNA fragments from 
exon 2 of patient 2 (Fig 16). 
1 2 3 4 
C Patient 2 c c 
Figure 16. An SSCP gel showing the banding pattern of the single strands 
from the PCR product of exon 2. The bands from patient 2 are shown in lane 2 
and surrounded by the bands from three control females (lanes 1, 3 and 4 ). 
Exon 2 was the only exon that yielded a band shift on SSCP analysis and was 
therefore sequenced to determine the base alteration. This proved to be an A to G 
transition at nucleotide position 271 which occurred in codon 46 and resulted in a 
substitution of arginine for lysine (K46R). The sequencing trace and summary 
details are given in figures 17 and 18 respectively. This mutation is not novel as it 
is currently listed as a polymorphism in the OTC mutation database. 
Polymorphisms are sequence alterations in the DNA that have no discernable 
impact on gene expression or gene product function. They also appear at 
frequencies of > 1 % in the general population. Mutations on the other hand are 
DNA sequence alterations that result in altered function of gene products, either 







265 267 268 269 270\2; 1 272 273 7 · 275 276 277 278 
268 269 270 271 2 273 274 275 tl6 277 278 
4:S 46 47 4R 
Figure 17. Aligned sections of the sequencing traces spanning codons 44 to 
48 of exon 2 of the pro band (A) and a control female (B). 
Complete exon sequencing 
It is common knowledge that SSCP coverage of sequence alterations is not 100% 
effective. It was therefore decided to sequence the remaining OTC exons from 
patient 2. These were duly carried out with each exon yielding normal coding and 
splice site sequences. 
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Abbreviation: 
Amino acid sequence: 























T L K N F 
Thr Leu Lys Asn Phe 
ACT CTA AAA AAC TTT 
ACT CTA AGA AAC TTT 
44 45 46 47 48 
Arn~ G 211 
K46R 


















Figure 18. A composite of the characteristics and nature of the polymorphism 
in exon 2 of the OTC gene of patient 2. Numbering is taken from the DNA 
sequence lodged in Genbank under accession number 000222. 
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Verification of the K46R polymorphism 
The A-to-G substitution at codon 46 of exon 2 in patient 2, created a cutting site 
for the restriction endonuclease Ddel which has the following recognition 
sequence: C J.. TNA G (Fig. 19A). The location of the cutting site within the 
exon is shown in fig. 198. Digestion of the PCR product from the mutant allele 
generates two fragments of sizes 126bp and 118bp which can be separated on a 
20% PAGE gel as shown in fig. 20. This polymorphism is reported as being a 
low frequency one, as it occurs in less than 10% of the population. (Grompe, 
1989) Interestingly, two of the six controls in our study also showed this 
polymorphism. (Fig. 20 lane 8). Screening of further controls to determine the 
frequency of this polymorphism in the South African population was not carried 
out. 
A. 
Abbreviated aa: T L K N F 
Wild type sequence: 5' ACT CTA AAA AAC TTT 3' 









---- 118bp ---+ ~ 126bp 
I 




Figure 19. A) The nucleotides in bold indicate the normal and mutated bases 
respectively. The underlined region represents the Ddel cutting site. B) A 
schematic presentation of exon 2 showing the position of the new Ddel site and 
the sizes of the exon 2 fragments generated by restriction of the PCR product. 
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Figure 20. Kindred 2: 
244bp 
126bp 
Restriction analysis of exon 2 with Ddel. Lane M: 
Molecular weight marker VIII, Lane 3: undigested PCR product of patient 2 
(244bp), Lane 4: digested PCR product of patient 2 (126bp and 118bp), Lanes 1, 
5, 7, 9, 11 &13: undigested amplified DNA (244bp) of controls, and Lanes 2, 6, 8, 
10, 12 & 14: digested PCR products of male controls. Controls in lane 6 and 8 had 
the common polymorphism. The l 18bp band has run off and is not visible on this 
gel. 
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Kindred 3, Patient 3 
PCR amplification of the OTC exons from patient 3 was successful for exons 1-4 
but not for exons 5, 6, 7, 8, 9, and 10 (Fig 21). These data are indicative of a 
partial deletion of the OTC gene, which incorporates exons 5-10 with one of the 
breakpoints occurring in intron 4. This mutation is novel as it is not listed in the 
OTC mutation database. Currently 5 large deletion mutations are recorded with 




Figure 21. A catalogue of some of the post-electrophoresis agarose gels, 
which show the successful amplification of exons 3 - 4 but not exons 5 - 10 from 
DNA of patient 3. M = DNA marker, B = Blank, 1 = PCR product from control 
DNA, 2 =PCR product from maternal DNA, 3 =unaffected brother, 4 =previously 
affected brother, and 5 =patient 3. 
61 
RFLP analysis and Southern Blotting 
Confirmation of the deletion mutation in patient 3, via the Southern Blotting (SB) 
technique was attempted but eventually discontinued due to major delay in 
probing the blot caused by the inadvertent use of a non OTC cDNA probe. Time 
constraints on the completion of the thesis did not allow for further southern 
blotting attempts. The basics of the SB method have however, been included in 
addition to the picture of the pretransfer gel as a significant period of time was 
expended on this method. The major delay was caused by an overseas laboratory, 
which supposedly sent us three OTC cDNA clones, which we eventually 
discovered were not OTC cDNA clones as the restriction patterns of several 
restriction enzymes differed from that predicted from the OTC cDNA sequence in 
Genbank. The clones received were labelled as DH5a pUC19 OTC, pHOEI, and 
pETOTCM2. The clone first utilised was pUCI 9 OTC with the insert cloned into 
the Pst 1 site of the plasmid. Digestion with Pst I gave an insert of the expected 
size of the OTC cDNA. This band was excised and purified, using a Qiagen Kit. 
PCR amplification was attempted using the OTC primers, which were supplied 
with the clone (pZ 106 and pZ 107), but was unsuccessful. These primers were 
thought to be the wrong primers. Numerous attempts at optimisation were made 
but without success .. It was then decided to check the identity of the cDNA insert 
by restriction digestion. 
The inserts from the other two clones, pHOEI and pETOTCM2 were also 
digested with various restriction enzymes and again the fragment patterns 
obtained differed from those expected from the OTC cDNA. By the time we 
received the correct OTC cDNA probe (Figures 23 and 24) from a different 
laboratory, my initial blot did not work and there was insufficient time available 
to repeat the blotting and probing procedures. 
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Restriction endonuclease digestion 
Before transfer, the digested electrophoresed DNA samples were photographed in 
the gel under UV light, allowing for calculation of molecular weights of bands to 
be observed on the autoradiograph (fig. 22.). 
M I -----------------19 
Figure 22. Electrophoresed genomic DNA samples digested with various 
restriction enzymes, prior to Southern blotting. The DNA samples were digested 
with enzymes, Pstl, Hind!IJ and EcoRJ, and loaded onto the gel as follows: Lane 
1, Molecular weight marker Hindi!! I EcoRJ; lane 2, control 1; lane 3, control 2; 
lane 4, mother of patient 3; lane 5, normal son; lane 6, previously affected son; 
lane 7, patient 3; lane 8, control 1; lane 9, control 2; lane 10, mother of patient 3; 
lane 11 , normal son; lane 12, previously affected son; lane 13, patient 3; lane 14, 
control 1; lane 15, control 2; lane 16, mother of patient 3; lane 17, normal son; 
lane 18, previously affected son; and lane 19, patient 3. 
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Generation of an OTC cDNA probe 
An authentic OTC cDNA probe was eventually prepared from clone pH0731 , 
kindly supplied by Dr. Wayne Fenton, Yale University. The full length OTC 
cDNA has a translatable size of 1065bp. Primers flanking the coding sequence 
were selected from the 5' and 3' non-translated regions of the OTC cDNA as 
shown in Fig. 23. These primers gave a cDNA probe of 1159bp in length (Fig 
24), which included all ten exons of the OTC gene. This fragment was labelled 
by nick translation, gel purified and used as a probe in the single hybridisation 
attempt. 
Forward 
s'!'lner cDNAEx 1-10 3' 
I -44bp~ 1-- 1065b 
p 
Reverse primer 
--------< ~ SObp ~ 
\ 
Figure 23 . 




Diagram of the OTC cDNA sequence of clone pH0731 , showing 
the location of the forward and reverse primers as well as the exonic sequence. 
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Figure 24. Polyacrylamide gel electrophoresis of the 1159bp PCR product 
amplified for the OTC cDNA (pH0731), which was used the hybridisation probe. 
Lane 1: Molecular weight marker VI; Lane 2, PCR blank; Lane 3, Control DNA 
exon 1 O; Lane 6, PCR product at annealing temp of 52°C; Lanes 8 & 9, Control 
DNA exon 1 and 10 respectively; Lane 11 , PCR product at annealing temp of 
55°C. Both annealing temperatures worked well for the amplification of the 
cDNA. Exons 1 and 10 were amplified in the same run to demonstrate primer 
amplification efficiency, as the respective forward and reverse primers were used 
to amplify the cDNA fragment of clone pH0731. 
Time constraints prevented further characterisation of the deletion through 
Southern blotting. 
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2.7. Discussion and Conclusion 
OTC deficiency is typical of other X-linked conditions where gene mutations are 
predominantly family specific or private, with only a few occurring recurrently 
and these at a frequency generally less than 5%. Although this absence of founder 
or population specific mutations complicates genetic diagnoses considerably, the 
effort involved is worthwhile as mutation identification provides accurate 
diagnosis, a reliable tool for carrier testing and prenatal diagnosis for which 
alternative biochemical and enzymatic methods are less reliable or invasive. 
This chapter has detailed the mutation workup in three kindreds with children 
affected by OTC deficiency. The mutation found in Kindred 1 was shown to be a 
T ~ A transversion in codon 104 of exon 4. This transversion converts the CTG 
(leucine) codon to CAG that codes for glutamine. This mutation (L104Q) is 
novel, as it is not listed in the OTC mutation database. Also in the same exon of 
this patient we identified a known polymorphism in codon 101. This 
polymorphism (transversion) converts the TT A codon for leucine to TIT, which 
codes for phenylalanine (L 101 F). Two findings suggest that L 104Q is a mutation 
and not a polymorphism. Firstly, the amino acid substitution is nonconservative, 
in that nonpolar leucine has been substituted by the polar glutamine. Secondly, 
other mutations have been reported in close proximity i.e. at codons 100, 102 and 
106, indicating that this section of the polypeptide chain is critical for enzyme 
function. It has also been shown that this specific region in exon 4 is highly 
conserved (table 1 ), which further strengthens the fact that this finding is a novel 
mutation. A stronger case could have been made if the L 104Q substitution was 
shown to be absent in a large number of chromosomes from control subjects. 
Ultimate verification however, must await mutagenesis, transfection studies and 
enzyme activity analysis 
While this study successfully identified a known polymorphism in the OTC gene 
in patient 2, it was unable to confirm the diagnosis of OTC deficiency through 
mutation detection. DNA from patient 2 was additionally subjected to PCR 
sequencing for each of the 10 exons of the OTC gene, but still without success. 
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Further gene studies in family 2 were not carried out as there is a strong 
possibility that the pro band falls into the 20-30% of OTC deficiency patients who 
manifest with a normal OTC coding and splice site sequence and presumably 
carry mutations in the promoter or intronic regions of the OTC gene. 
The mutation in kindred 3 was shown to be a large intragenic deletion removing 
exons 5 - 10. The size of this deletion is unknown but it was shown, through the 
use of OTC microsatellites (see chapter 4) to be less than 1 cM as two of the 
flanking OTC markers (DXS8090 and DXS8113) could be amplified; these two 
markers are approximately 1 cM apart. This null mutation is likely to generate an 
unstable partial OTC mRNA as it lacks exon 10 and the 3' untranslated region, 
which contains the polyadenalation signal. If translation does occur then the 
truncated protein produced is likely to be rapidly degraded. 
The failure of mutation detection in Kindred 2 has implications for prenatal 
diagnosis in that male foetuses conceived in the future, will have to be screened 
using microsatellite markers for the OTC gene. This microsatellite approach was 
in fact used for Kindred 3 where prenatal diagnosis was requested in two 
pregnancies before the mutation in this family had been characterised (refer to 
chapter 4). The choice for microsatellite usage in kindred 2 was given by the 
strong history of X-linked inheritance, through the multiple early male deaths, and 
the clinical and laboratory presentation of OTC deficiency in the pro band. 
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Chapter 3.1: Mutation analysis and X-inactivation studies: Kindred 4 
Overview 
This kindred has been dealt with in a separate chapter as the proband, patient 4, while 
presenting with the entire hallmark features of late onset OTC deficiency was also 
found to have Klinefelter's syndrome. Considerable time has been spent in trying to 
substantiate the presence of OTC deficiency in the face of Klinefelter's syndrome 
where the patient now has two copies of the X chromosome. 
Patient 4 
Patient 4 was born in 1996 and is part of a singleton family (Fig 25). His neonatal 
period was relatively uneventful and he remained well until the age of 18 months 
when his health deteriorated and he started having episodes of vomiting and 
associated periods of ataxia and intentional tremor. 
DOB 6/3/96 
' 
Figure 25. The family tree of patient 4. 
He was referred to Red Cross Children's Hospital at this time and was diagnosed with 
hepatitis and subsequently sent home. Shortly afterwards, he presented with self-
mutilating behaviour, recurrent episodes of vomiting and lethargy, ataxia, and 
seizures. Blood ammonia was recorded at 600 µMols/L (normal <50). These 
symptoms were suggestive of a late onset urea cycle defect with OTC deficiency 
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being the most likely candidate. Plasma amino acid levels were found to be normal 
as was the citrulline level. Urine orotic acid excretion was found to be more than 
three times normal at 11.1 nM/L (normal = <3). The clinical and laboratory 
presentation was compatible with OTC deficiency, which is the most common of the 
urea cycle defects. 
DNA studies 
The diagnosis of OTC deficiency is usually based on a liver biopsy and assay of OTC 
activity. This option however, was not available for this patient and it was decided to 
screen genomic DNA for mutations in the OTC gene. PCR followed by SSCP was 
performed on all the exons and no evidence was found for any exonic mutations. 
The next step in the workup in this patient would have been the sequencing of each of 
the 10 exons of the OTC gene, as it is known that mutation detection via the SSCP 
technique is not I 00% effective. However, during the SSCP studies it was 
discovered that DNA from patient 4 had earlier been sent to an overseas laboratory 
for sequencing. This sequencing exercise had been terminated when preliminary 
results indicated the presence of two copies of the X-chromosome. Patient 4 had then 
been karyotyped and were found to have Klinefelter' s syndrome (47XXY). 
Given this new information, it was decided to expand the range of methodologies 
normally employed in mutation detection studies, by determining whether skewed X-
inactivation accounted for the combination of OTC deficiency and Klinefelter 's in 
our patient. This investigation would also determine whether two copies of the 
mutant X-chromosome had been inherited from his mother. Comprehensive 
sequencing of all the OTC exons was to be undertaken after this investigation. 
X-inactivation 
Background: Males have one X chromosome, while females have two. This creates a 
dosage imbalance for X linked genes, which is addressed by the cell through the 
inactivation of one of the X chromosomes, leading to an active and an inactive 
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chromosome. The latter X chromosome can be distinguished by the fact that it is late 
replicating, methylated at the gene control regions, transcriptionally repressed and 
heterochromatic. Inactivation occurs during at the blastocyte stage of development 
is random. Females therefore who are heterozygous for X-linked traits should have 
half their cells expressing either of the X chromosomes. In reality, 5 to I 0% of 
normal females demonstrate non-random inactivation and are said to be skewed for X 
inactivation. In this scenario, the cell type expressing one X will predominate over 
the other cell types. So, in females heterozygous for an X-linked disorder, the degree 
of skewing will correlate with the degree to which they demonstrate symptoms of the 
disorder. X inactivation therefore plays a key role in the clinical phenotype in female 
carriers of X-linked diseases. In fact this was first recognized by Lyon in 1961 when 
he observed that females heterozygous for X-linked genes showed mosaic expression 
(Willard, H.F, 1995). 
X inactivation requires a locus, the X inactivation center (X-IC) on the long arm of 
the X chromosome for inactivation to occur. The X-IST (X-inactivation specific 
transcript) gene maps within the X-IC region and plays a role in X inactivation. 
(Puck, J.M and Willard, H. F, 1998) X-IST is only expressed from the X 
chromosome selected for inactivation and produces an RNA molecule that spreads an 
inactivation signal in cis up and down the X chromosome while remaining associated 
with the inactivated X chromosome. (Willard, H.F, 1995). 
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Fig 26. Three mechanisms leading to a Skewed pattern of X chromosome 
Inactivation. (Puck, J.M and Willard, HF, 1998) 
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X inactivation is maintained during cellular proliferation and differentiation by 
continued expression of the X-IST gene and by the methylation of DNA cytosine 
residues on the inactive X chromosome (Fig 26a). If one X chromosome carries a 
gene defect that is detrimental to proliferation and/or survival of a particular cell type, 
then all cells of that lineage will die and the only cells remaining will be those 
preferentially inactivating the mutated X chromosome (Fig 26b) (Puck, J.M and 
Willard, H.F, 1998). In Fig 26c, a mutation in the X-IST gene results in the non-
random selection of the X chromosome to be inactivated. The red arrow indicates the 
production of X-IST RNA that spreads an inactivation signal up and down the X 
chromosome. 
Determination of X-inactivation status 
The X inactivation pattern in women can be derived from examination of a 
trinucleotide repeat microsatellite in the first exon of the human androgen-receptor 
gene (HUMARA) (fig. 27). Two methylation sensitive Hpall sites occur less than 
I OObp away from this microsatellite and have been exploited in a PCR based assay, 
which can distinguish between the active and inactive X chromosome. This assay 
utilizes primers, which yield a PCR product of approximately 280 bp that includes the 








Fig. 27. Exon I of the HUMARA locus showing the locations of the Forward (F) and 
Reverse (R) PCR primers, the CAG repeat and the Hpa/1 sites (Wengler G. S. et al , 
1997). 
When the template DNA is digested, prior to PCR amplification, with Hpa/1, a 
methyl sensitive restriction enzyme, amplification only occurs from the allele where 
Hpa/1 restriction sites are methylated. This occurs because the template allele 
containing unmethylated Hpa/1 sites is digested and destroyed by Hpa/1 A product 
will thus only be obtained from the inactivated X chromosome that carries the 
methylated template (Allen, R. C. et al , 1992). 
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Because of the highly polymorphic character of the STR most females yield 2 bands 
of different lengths on electrophoresis. Males with only one X chromosome yield 
one band when amplified (fig. 28); females yielding I PCR band on electrophoresis 
carry the same length repeat on each of their X chromosomes. 
Lane 1 2 3 4 5 
~ ~ ~ ~ ~ 
-Hpall +Hpall +Hpall -Hpall +Hpall 
Random non-random 
X-inactivation 
Fig. 28. Graphical representation of the electrophoretic separation of the PCR 
products derived from the CAG triplet repeat in exon I of the HUMARA gene. Lane 
I, the two banded pattern from a women, heterozygous for triplet repeat lengths, prior 
to Hpa/1 digestion; lane 2, the banding pattern from the same women post HpaII 
digestion, showing random X-inactivation; lane 3, the banding pattern from a women 
showing partial skewing of X-inactivation; lanes 4 and 5, the respective band patterns 
from a man before and after Hpa/1 digestion of genomic DNA. 
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Chapter 3.2: Methods 
3.2.1. DNA extraction and quantitation 
3.2.1.1. Genomic DNA extraction protocol 
3.2.1.1.1. Whole blood extraction method (refer to 2.5.1.1.) 
3.2.1.1.2. Frozen blood extraction method (refer to 2.5.1.2.) 
The concentration, purity and integrity of the DNA was determined by measuring the 








Determination of DNA concentration 
By Spectrophotometric readings A260 (refer to 2.5.2.1 
By agarose gel electrophoresis (refer to 2.5.2.2.) 
Restriction digestion 
Protocol for digestion 
The following quantities were added to the reaction mixes per 20 µI volume: 
IO x Buffer L 2.0 µI 
0.4% Casein 2.0 µI 
0.04% BSA 0.2 µI 
distilled water 9.8 µI 
Hpa ll(IOU/µI) enzyme 2.0 µI 
DNA (2µg) 4.0 µI 
20 ~ti 
Samples were incubated @ 37°C overnight. A further 10 U(l µI) Hpa II was added 
and again the samples digested for another 2 hours. The mixtures were then heat-






The reaction mixtures per l sample of 50 µl contained the following volumes: 
2.5 mM dNTP mix 4.0 µI 
10 x PCR buffer 4.5 µI 
25 mMMgCh l.O µI 
20 pM ANDR-f primer l.O µI 
20 pM ANDR-r primer l.O µI 
distilled water 28.5 µI 
digested DNA 4.0 µI 
45 µI 
Control samples without DNA were also included. PCR mixtures were overlaid with 
mineral oil (45 µI) to prevent evaporation and condensation of the samples. Tubes 
were placed in a thermocycler and subjected to a "hot start" by the addition of the 5 
µI enzyme mix after the first 95°C for 5 minutes step in the PCR cycle. 
An enzyme mix contained the following quantities per reaction: 
Taq polymerase 







3.2.4.2. PCR thermocycling 
The following programme was used: 
Step 1. Denaturation at 95°C for 5 minutes 
This was set for 1 cycle 
11. denaturation at 94°C for 30 seconds 
m. annealing at 58°C for 30 seconds 
1v. extension at 72°C for 40 seconds 
This was repeated for 28 cycles 
3.2.5. 
3.2.5.1. 
v. Final extension at 72°C for 7 minutes 
Polyacrylamide gel electrophoresis 
Preparation of plates 
Plates were prepared as in section 2.4.1 and 2.4.2 with a few modifications. Two 
small plates (150 mm x 150 mm) were used instead of the 2 large (300 mm x 400 
mm) plates; 0.75 mm spacers and comb were used instead of the 1 mm spacers and 
comb. 
3.2.5.2. Preparation of PAGE gel 
The following volumes were added to make the polyacrylamide gel: 
20%Acrylamide (19:1) 12.0 ml 
5 x TBE 4.8ml 
Urea 4.8 g 
10%APS 240 µl 
distilled water 7.2 ml 
TE MED 15 µl 
- 24 ml 
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A well-forming comb was inserted at the top of the two plates and side-clamps were 
used to hold the plates firmly together. The solution was gently mixed, taken up in a 
20 ml syringe and poured between the two plates, which were lying on a flat surface. 
Polymerisation occurred in about 90 minutes. The gels were then ready for use. 
3.2.5.3. Sample preparation and electrophoresis 
An aliquot (5 µI) of the PCR product was mixed with 2 µl of the 6 x loading dye. 
Combs were removed from the gel to form the wells. The gel was placed into the 
electrophoresis tank and filled with 1 x TBE buffer. Prior to loading, wells were 
cleaned of urea by rinsing with tank buffer with the aid of a syringe. The gel was run 
at room temperature@ 65W overnight. 
3.2.6. Visualisation of PCR products 
3.2.6.1. Silver stain 
Following electrophoresis and disassembly the plate containing the gel was placed in 
a gel tray for silver staining. The gel was covered with 2 litres of distilled water and 
gently agitated for I minute. The water was discarded and Silver Nitrate solution 
(solution I) added. The tray was slowly agitated for 10-15 minutes, whereupon 
Solution I was decanted and replaced by distilled water. After shaking for a further 2 
minutes, the water was discarded and solution 2 added to the tray. Agitation was 
continued for I 0-15 minutes or until bands were clearly visible. Solution 2 was 
discarded and water added to the tray, which was agitated for a further minute. 
Thereafter the water was discarded and solution 3 was added to the tray to sharpen 
the bands. Solution 3 was discarded and the gel reimmersed in water. The gel was 
then viewed and photographed on a light box. The glass plates were soaked in 0.5 M 
NaOH to remove the gel from the plate. The plates were given a comprehensive rinse 
and then stored for the next gel. 
The exons showing a band shift were then amplified through PCR, purified and 
submitted for sequence analysis. 
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3.2.6.2. Ethidium bromide stain 
9 µI of EtBr was mixed in 125 ml of 5 x TBE 
The gel was gently lifted off the plate and soaked in the EtBr solution (10 mg/ml) for 
30 minutes and visualised on the UV transilluminator. 
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Chapter 3.3: Results, 
3.3.1. X-inactivation studies 
The microsatellite marker in exon 1 of the Human Androgen Receptor gene was 
amplified by PCR using both Hpall digested and undigested genomic DNA, which 
had been isolated from leucocytes of patient 4. The PCR products were run on non-
denaturing PAGE gels and were visualised by silver staining (Fig 29). The two faint 




Fig. 29. Polyacrylamide gel electrophoresis of the PCR products from the 
microsatellite marker in exon 1 of the Androgen Receptor gene. Lane M, Molecular 
weight marker; lane 1, PCR product of undigested genomic DNA of patient 4; lane 2, 
PCR product of digested genomic DNA of patient 4; lane 3, PCR product of undigested 
genomic DNA of male control 1; lane 4, PCR product of digested genomic DNA of 
male control 1; lane 5, PCR product of undigested genomic DNA of male control 2, 
lane 6, PCR product of digested genomic DNA of male control 2. 
3.3.2. OTC gene sequencing 
Each of the 10 exons of the OTC gene in patient 4 have been sequenced and in each 
case, normal coding and splice site sequences were recorded. 
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3.4. Discussion and Conclusion 
The coexistence of Klinefelter's syndrome with OTC deficiency was a significant 
complicating factor in the diagnostic workup of patient 4. Carrier females for OTC 
deficiency can present clinically, and this is usually due to skewed X-inactivation in 
the liver, where the majority of hepatocytes have inactivated the normal X-
chromosome. Skewing of X-inactivation was thus, also a possibility in our patient as 
Klinefelter's patients always inactivate one of the X-chromosomes in all their cells. 
There was however a second possibility in our patient and that was the inheritance of 
two copies of the mutant X-chromosome. Both these possibilities were explored by 
PCR analysis as described above. 
It is clear from the amplicon banding pattern in Fig 29, that X-inactivation in patient 4 
was random. This can be seen by the equivalent intensities of the PCR bands after 
Hpa!I digestion of genomic DNA. It is also clear from these data that patient 4 had 
inherited two different copies of the X-chromosome. In studies not shown here, the 
two microsatellite repeat lengths were found to be the same as the repeat length sizes 
from his mother and it is likely that he has inherited both of his mother ' s X-
chromosomes. Paternal DNA was not available to confirm this assumption. 
Although we have shown random X-inactivation in white-cell DNA from our patient 
we have not ruled out skewing of X-inactivation as a feature in the aetiology of OTC 
deficiency as presenting females have been described where skewing is evident in the 
liver but not in circulating white-cells. This situation was reported, for example in a 
Japanese famil y of OTC carrier females (Yorifuji , T, et al , 1998), where X-
inactivation patterns in the liver differed significantly from that of the peripheral 
blood leukocytes and even within the same liver. X-inactivation studies therefore, 
need to be carefully evaluated although in most cases, analysis of peripheral blood 
leukocytes satisfactorily reflects the X-inactivation status of the individual in other 
organs. Unfortunately in our study, a liver biopsy from patient 4 was not available 
to allow examination of this possibility. 
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The finding of normal coding and splice sequence for each of the IO exons of the 
OTC gene from patient 4 was disappointing. However, this finding does not rule out 
an OTC gene defect as 20% of OTC deficient subjects present with similar results 
and are presumed to have a mutation elsewhere in the OTC gene, perhaps in the 
promoter region or in an intronic enhancer, or in some other gene implicated in OTC 
function. 
To summanse the findings for patient 4. Initially, he started out as a strong 
candidate for the late-onset form OTC deficiency, but there is now considerable doubt 
about this diagnosis. This has arisen firstly, from the finding of a normal coding 
sequence for the OTC gene. However, 20 - 30% of patients with OTC deficiency do 
not have OTC gene mutations and are known as OTC "phenocopies" . Our patient 
could thus possibly reside in this category into which we would put patient 2. 
However, the presence of Klinefelter' s syndrome distinguishes this patient further 
and casts further doubt on the diagnosis as our patient shows heterodisomy for the X 
chromosome and must therefore show skewing of X-inactivation in his liver. This 
again is the less likely situation as <30% of carrier females show pathological 
skewing in the liver and then again, only a small portion of these woman show 
random skewing in white cells, which is the finding in our patient. (Yorifuji , T, et al , 
1998) 
Direct evidence for OTC deficiency in patient 4 would have come from enzyme 
studies on liver tissue but this was not an option for this laboratory. The evidence we 
have sought has been indirect and the findin gs now indicate that patient 4 is only a 
weak candidate for OTC deficiency but a much stronger candidate for that rare 
category of defect known as the OTC " Phenocopy". 
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Chapter 4.1: OTC microsatellite markers 
Overview 
This section details the findings of the prenatal diagnosis, using rnicrosatellite 
markers, which was performed when the mother of patient 3 (kindred 3) became 
pregnant, and was found to be carrying a male foetus. At this stage although liver 
enzyme for OTC deficiency had not been performed, OTC deficiency was 
considered to be a strong enough candidate to justify the use of rnicrosatellites in 
linkage analysis for the prenatal diagnosis. The reasons being, two previous male 
deaths in the neonatal period of this family, and the typical clinical presentation in 
patient 3, which included dramatically elevated blood ammonia and urinary orotic 
acid levels. Subsequent to the first prenatal diagnosis, OTC deficiency was 
conclusively shown by the mutation screening that was performed on DNA from 
patient 3. Consequently, the mother in this family is an obligate carrier for OTC 
deficiency. 
Microsatellites 
Microsatellites are DNA repeat sequences which have been used as markers in 
linkage studies and mapping, and occur frequently in the non-coding regions of 
the human genome. (URL 8) They consist of highly repetitive specific DNA 
sequences (DNA repeats) which occur as tandem repeats of varying length. They 
are also known as VNTR's (Variable Number Tandem Repeats), and are unique 
to each person. (URL. 9) The size of the repeating unit varies between 2 - 6bp, 
with CA repeats being the most commonly encountered. Typical examples of a di 
and tri-nucleotide repeat are shown in figure 30. 
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CA Dinucleotide repeat 
ATGGAATCGCACACACACACACAGCACTACTACAGG 
TACCTTAGCGTGTGTGTGTGTGTCGTGATGATGTCC 
TAC Trinucleotide repeat 
TTTACAGGGCTACTACTACTACTACTACTTGATGAT 
AAATGTCCCGATGATGATGATGATGATGAACTACTA 
Fig 30. Examples of a dinucleotide (CA) and a trinucleotide (TAC) microsatellite 
repeat. 
The flanking reg10ns of each microsatellite are of unique sequence and are 
specific to each microsatellite. Individual microsatellites can thus be targeted by 
PCR using primer sequences selected from the flanking regions. The number of 
repeats varies from individual to individual and generally ranges between 10 to 28 
in number. Following PCR the resulting amplicons can then sized and scored as 
alleles. Depending on the sizes of these alleles, an individual can be homozygous 
or heterozygous; homozygous, when the allele sizes are equal and heterozygous 
when the allele sizes are not the same. A given microsatellite locus can have as 
many as 5 to 15 alleles for a typical vertebrate population. It is possible to 
perform powerful genetic analysis when many or several loci are being analysed. 
Analyses of microsatellites are usually done by fluorescent labelling of PCR 
product and capillary electrophoresis (URL. 10). This study however, used 
amplicons labelled with radioactive [ y32P] ATP, followed by chromatography on 
denaturing PAGE and autoradiography. 
It has been estimated that microsatellites have an average mutation rate of 0-7x 
10-3 mutations I locus I gamete I generation. (Brinkmann et al, 1998) Two 
favoured mechanisms are those involving unequal crossing over during meiosis 
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and strand-slippage during replication. (Forbes et. al, 1995). The latter 
mechanism appears to be the predominant one accounting for the variation in the 
lengths of microsatellites. The variation in length of the microsatellite is likely to 
occur during the lagging strand synthesis at the replication fork (Fig 31 ). During 
the dissociation of the polymerase complex (Fig 3 lc), a newly synthesized DNA 
strand slips, leading to the formation of a transient bulge. In the absence of DNA 
repair, the repeat increases in length. Alternatively, if the transient bulge forms on 
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Fig 31. The Strand-slippage replication model of microsatellite length mutation 
(taken from URL 12). 
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Applications of satellites 
Microsatellites have three useful features. Firstly, they are suitable for PCR 
amplification because of their small size (less than 1 OObp ). Secondly, single copy 
nuclear DNA makes up the flanking regions, allowing for specificity in the PCR 
reaction and thirdly, they have high mutation rates. (URL. 12) 
"Microsatellites have found extensive use in genome mapping studies and have 
also served as ideal markers for defective alleles in segregation analysis of 
familial disorders". (URL. 13) Other applications of microsatellites include 
population genetics, prenatal diagnosis, paternity testing and forensics analysis. 
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Chapter 4.2 Methods 
4.2.1. 
4.2.1.1. 
Primer end-labelling for a sizing ladder or gene. 
Labelling protocol 
The reaction mix for a ladder of 10 µl volume was as follows: 
10 x PNK buffer 1.0 µl 
-40 Primer (5 µM) 0.8 µl 
Distilled water 4.2 µl 
[y32P] ATP 3.0 µl 
*Diluted T4 PNK (5 U/µl) 1.0 µl 
10 µl 
The reaction mix for a microsatellite of 20 µl volume was as follows: 
10 x PNK buffer 2.0 µl 
Primer Forward (20 pM) 5.0 µl 
Distilled water 9.5 µl 
[y32P] ATP 1.5 µl 
*Diluted T4 PNK (5 U/µl) 2.0 µl 
20 µl 
The samples were incubated at 3 7°C for 2 hours. Time is not critical and the tubes 
can be left overnight. Samples were heat inactivated at 90°C for 3 minutes or 
65°C for 5 minutes, given a brief spin and stored at -20°C until use. 
*(Dilute 30 U 1 in 6, i.e. 0.6 µl PNK + 3.0 µl PNK buffer. NB. The diluted 




Protocol for sizing ladder synthesis 
PCR preparation of a DNA ladder using cycle sequencing 
A PCR reaction mixture with a 35.6 µl volume was prepared as follows: 
Ml 3 DNA single stranded 5.0 µl 
10 x Taq buffer 4.47 µl 
Radiolabelled -40 Primer 2.83 µI 
Distilled water 18.53 µl 
Taq (5 U/µl) 0.3 µl 
MgC}i 4.47 µl 
35.6 µl 
Four microlitres (4 µl) of ddATP + dNTP and ddTTP + dNTP mixes were 
aliquoted into two clean tubes (this mix contained the dNTP's and the specific 
ddNTP). 
Aliquots of 500 µl were made up as follows: 
Tubel (ddATP+dNTP) 
25 µl dNTP 
65 µl ddNTP 
410 µl distilled water 
500 µI 
tube 2 (ddTTP+dNTP) 
25 µI dNTP 
75 µI ddNTP 
400 µI distilled water 
500 µl 
Into each ddA TP and ddTTP tube, 16 µI of the above reaction mix was aliquoted 
and overlaid with mineral oil. 
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4.2.2.2. PCR Thermocycling 
The following programme was used: 
Step 1. Denaturation at 94 °C for2 minutes 
This was set for 1 cycle 
n. denaturation at 94°C for 30 seconds 
111. annealing at 55°C for 30 seconds 
1v. extension at 72°C for 1 minute 
This was repeated for 28 cycles 
v. Final extension at 72°C for 5-10 minutes 
The reactions were terminated by the addition of 8 µl formamide stop mix. Both 
tubes were mixed together and stored at -20°C. The samples were denatured for 
2-5 minutes @ 95°C before loading. Aliquots of the ladder ( 4 µl ) were included 
in each run. 
4.2.2.3. Preparation of sizing ladder using the Sequenase KIT 
A reaction mix with a 29 µl volume was prepared as follows: 
M13 DNA single stranded 10.0 µl 
Reaction buffer 






The sample was incubated at 65°C for 2 minutes, slowly allowed to cool to room 
temperature for 15-30 minutes, centrifuged and cooled on ice. 







l O ~Li 
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The 39 µI mix was divided equally (16 µI) into the 2 termination tubes. 
The termination tubes had been prepared in advance, had been preheated to 3 7°C 
and now contained the following: tube 1; 4 µI ddATP; tube 2, 4 µI ddTTP. The 
two tubes were gently mixed and incubated at 37°C for 5 minutes followed by 
70°C for 7 minutes and then 14 µI of stop solution was added to each reaction 
tube. The two mixes were combined, mixed, spun and stored at -20°C. The 
ladder was heated to 95°C for 5 minutes before loading onto the gel. 
*(Dilute 0.5 µI sequenase, 0.5 µI pyrophosphate and 3 µI buffer) 
4.2.3. 
4.2.3.1 
Radioactive PCR reaction 
PCR protocol 
A reaction mix containing a 10.0µ1 volume was prepared as follows: 
10 x Reaction Buffer 1.0 µI 
50 mM MgC12 0.4 µI 
5 mM dNTP's 0.66 µI 
Reverse primer (20 pM) 
dH20 
Taq Polymerase enzyme 
End-labelled Forward primer (20 pM) 







The 10.0 µI reaction sample was overlaid with 10 µI light mineral oil (Sigma) and 
briefly centrifuged. The tubes were placed in a thermocycler. 
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4.2.3.2. Thermocycling 
An appropriate temperature profile for the thermocycling process was derived 
from the sequence of the forward and reverse primers. 
The following programme was used: 
Step 1. Denaturation at 95°C for2 minutes 
This was set for 1 cycle 
n. denaturation at 95°C for 45 seconds 
v1. annealing at 55°C for 45 seconds 
vn. extension at 72°C for 45 seconds 
This was repeated for 30 cycles 
v111. Final extension at 72°C for 5-10 minutes 
This temperature profile was suitable for all primers used. 
To each sample 4 µl of stop solution was added and the samples were stored until 
ready for use. 
4.2.4. 
4.2.4.1. 
Polyacrylamide gel electrophoresis 
Preparation of plates 
The plates were prepared as in section 2.4.2 with a few slight modifications. No 
plate glue was used on either plate. Shark-tooth combs of size Imm were used for 
the formation of wells. 
The surfaces of both plates were thoroughly washed with detergent and 70% 
ethanol and allowed to dry completely. Gel slick was applied to one plate and 
vigorously rubbed onto the surface. The plates were assembled and secured with 
the aid of bulldog clips and with spacers (0.4 mm) separating the two plates. 
Shark-tooth combs of size 1 mm were used for the formation of wells. 
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4.2.4.2. Preparation of PAGE gels 
Gels were prepared from the following mix: 
6% cold Polyacrylamide working stock 





4.2.4.3. Sample preparation and electrophoresis 
The gel was pre-electrophoresed for 30 minutes at 65W in 1 x TBE buffer. Prior 
to loading, PCR samples and the ladder were heated for 3 minutes @ 95°C and 
immediately placed on ice. Samples were loaded and the gel was run for 3 hours 
@ 65W. 
4.2.4.4. Drying and auto radiography of the gel 
At the end of electrophoresis, the power to the gel was disconnected and the TBE 
was discarded from the buffer chambers. The lower chamber was disposed in the 
radioactive waste container as it contained unincorporated radiolabel and 
radioactively-labelled short DNA molecules. A thin spatula was inserted between 
the plates and twisted to gently separate the plates. The gel adhered to the larger 
non-silanized plate. 3MM Chromatography paper was cut to a suitable size and in 
one smooth movement it was gently pressed down to ensure good gel to paper 
contact. Starting at one corner at the well end of the gel, the paper was peeled 
back and the gel adhered securely to it. A layer of Saran plastic wrap was placed 
on top of the gel and the paper/gel/plastic was then trimmed. The gel was then 
positioned, paper side down on gel drier and dried under vacuum @ 80°C for at 
least 90 minutes. In a darkroom illuminated with a safety light, the gel was placed 
in direct contact with a film sheet ( autorad), inside a film cassette. The film was 
exposed for its desired length of time (12-24 hours) and at an appropriate 
temperature (room temperature). The time of exposure depended on the strength 
of the radioactivity in the sample, and in most cases, was determined empirically 




Visualisation of the Microsatellites 
Protocol for developing the X-ray film 
After exposure, the film was removed from the cassette in the darkroom ( using the 
safety light only) for developing. The film was immersed in the developer 
solution for 90 seconds, then in stop solution for 30 seconds and the in the fixer 
solution for 2 minutes. The film was then placed in running tap water for 5 
minutes and left to dry. The alleles were then scored according to the relative 
positions of the exposed bands. 
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Chapter 4.3.1: Microsatellite Results 
A search of the human genome database for microsatellites flanking the OTC 
gene revealed three that seemed suitable. These were DXS8090, DXS 1068 and 
DXS8113, with the outside pair being separated by a distance of 3cM, which 
gives recombination probability of approximately 3%. The search was done using 
the following web address: 
http://www.ncbi.nlm.nih.gov/genemap98/map.cgi?MAP=GB4&BIN=610&amp; 
MARK=WI-9177 
1 2 3 
-3cM 
Figure 32. Diagram of the OTC gene showing the location of the microsatellite 
markers DXS8090, DXS1068, and DXS8113. 
Table 2 Details of the selected microsatellite markers which flank the OTC gene. 
Locus Heterozygosity PCR Primer Sequence 
index 5' -3' 
DXS 8090 0.81 Forward GGGTGAAA TTCCA TCACAAA 
Reverse ACAAA TGCAGA TGT ACAAAAAA TA 
DXS 1068 0.79 Forward CCTCTAAAGCATAGGGTCCA 
Reverse CCATCTGAGAACACGCTG 
DXS 8113 0.68 Forward CCTCT ACA T AGGCACA TGC 




154 - 172 
245 - 259 
229 - 239 
DNA from the mother, unaffected son, affected son (patient 3), previously 
affected son and the foetus was amplified by PCR in the presence of 32PadA TP 
and primer pairs for each of the 3 microsatellites. PCR products were separated 
on a 6% polyacrylamide gel. 
For microsatellites to be informative in this family, it would be necessary for the 
mother of patient 3 to carry different length repeats on her X-chromosomes. This 
would enable the mutant allele to be identified through PCR of the OTC allele 
from the previously affected sibling. Each of the microsatellites, was amplified 
from maternal DNA with only DXS8090 distinguishing between the two alleles 
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Figure 33. Autoradiograph showing OTC microsatellite marker DXS8090 for the 
family of patient 3. M depicts the sizing ladders used. Lane 1- mother (1 ,2), lane 
2- unaffected son (1 ), lane 3- patient 3 (previously affected son) (2), lane 4- foetus 
(2) and lane 5- affected son (2). Allele 1 = 168bp and allele 2 = 166bp. 
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The two maternal alleles were clearly distinguishable, enabling accurate scoring 
for each sibling. It was clear from the autoradiograph that maternal allele 2 
carried the mutant OTC gene as this was the allele inherited by both of the 
affected sons. Unfortunately this allele had also been inherited by the foetus and 
was thus indicative of OTC deficiency. The diagnosis of an affected male foetus 
was communicated to the parents who then elected to terminate the pregnancy. 
Approximately eighteen months later, the mother returned to the hospital, 
pregnant and requested another prenatal diagnosis. At the time of doing the 
microsatellite analysis the gender of the foetus was unknown. Even though the 
mutation was known at this stage, microsatellite analysis was used in the second 
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Figure 34. Autoradiograph of a PAGE gel showing the OTC microsatellite 
marker DXS8090 for the family of patient 3 (second pregnancy). Lane 1- mother, 
lane 2- unaffected son, lane 4- patient 3 (affected son), lane 5 & 6- foetus and M 
depicts the sizing ladder used. Allele 1 = 168bp and allele 2 = 166bp. 
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The DXS8090 genotype recorded for the foetus clearly demonstrated that the 
gender was female and that the defective OTC allele (allele 2) had been inherited 
from the mother, according carrier status to the foetus. The diagnosis of a carrier 
female foetus was communicated to the parents, who were eventually delivered of 
a healthy daughter. 
Chapter 4.3.2: OTC Microsatellite markers in the South African 
Population 
A survey of 3 ethnic groups 
Heterozygosity indexes of DXS8090, DXS1068 and DXS8113 in the South 
African population. 
The lack of informativeness in two out of the three microsatellites analysed in this 
family was unexpected, as both have yielded high heterozygosity indexes ( <0.68) 
in other populations. 
The primary objective of this study was to determine the range of repeat lengths 
and the heterozygosity indexes of DXS8090, DXS 1068 and DXS81 l 3 in South 
Africans from different racial backgrounds. These data would allow for a ranking 
of the microsatellites in order of increasing likelihood of being informative in 
future OTC diagnostic interventions. Unrelated individuals of the racial 
groupings African, Mixed ancestry and Caucasian, were chosen for this study. 
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DXS8090 
The autoradiograph demonstrating the vanous allele sizes for microsatellite 
DXS8090 in the African population is shown in fig. 35 A and B. Males and 
females have been run on different gels. 
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Figure 35 A. Autoradiograph of PAGE gels run to determine size distribution of 
the microsatellite marker DXS8090 in African females. The sizes shown 
represent the length in bp of the PCR amplicons; individual CA repeat numbers 
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Figure 35 B. Autoradiograph of PAGE gels run to determine the size 
distribution of the microsatellite marker DXS8090 in African males. The DNA 
ladder used to determine the size is not shown. 
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The allele sizes, distribution and frequencies for this locus for the different ethnic 
groups are shown in Table 2 and fig. 36. 
Table 3. Allele sizes distribution and frequencies for Microsatellite DXS8090 
Allele sizes, distribution and frequencies for Microsatellite marker 
DXS8090 
n n n 



























0 1 0.01 0 
0 4 0.039 0 
0 0 0 4 
0.012 0 0 7 
0.085 3 0.029 11 
0.073 9 0.088 7 
0.146 17 0.167 17 
0.122 11 0.108 8 
0.061 8 0.078 14 
0.427 22 0.216 2 
0.061 19 0.186 2 
0.012 8 0.078 2 
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Figure 36. Graphical presentation of the allele frequency distribution amongst 
the three populations for microsatellite marker DXS8090. 
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DXS1068 
The autoradiographs demonstrating the vanous allele sizes for microsatellite 
DXS1068 in the African and Caucasian populations is shown in fig 37 A and B. 
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Figure 37 A. Autoradiograph of PAGE gels run to determine size distribution of 
the microsatellite marker DXS1068 in African males and females. The DNA 
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Figure 37 B. Autoradiograph of PAGE gels run to determine size distribution of 
the microsatellite marker DXS 1068 in Caucasian males and females. The DNA 
ladder used to determine the size is not shown. 
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The allele sizes, distribution and frequencies for this locus for the different ethnic 
groups are shown in Table 3 and fig. 38. 
Table 4. Allele sizes, distribution and frequencies for Microsatellite DXS 1068 
Allele sizes, distribution and frequencies for Microsatellite marker 
DXS1068 
n n n 
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0.013 10 0.109 7 
0.01 3 7 0.076 12 
0.092 16 0.174 14 
0.053 11 0.12 14 
0.105 10 0.109 0 
0.289 5 0.054 2 
0.171 27 0.293 14 
0.263 6 0.065 7 
Allele Frequency distribution for DXS1068 

















Figure 38. Graphical presentation of the allele frequency distribution amongst 
the three populations for microsatellite marker DXS 1068. 
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DXS8113 
The autoradiographs demonstrating the vanous allele sizes for microsatellite 








Figure 39 A. Autoradiography of PAGE gels run to determine the size distribution 
of the microsatellite marker DXS8113 in African Females. The DNA ladder used 
to determine the size is not shown. 
237bp j'r-',?>,-,:,, ... f-------~-==----1237bp 
- -------l235bp 
.iWiii4-------j23 l bp 
African Males 
Figure 39 B. Autoradiography of PAGE gels run to determine the size distribution 
of the microsatellite marker DXS8113 in African Males. The DNA ladder used to 
determine the size is not shown. 
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The allele sizes and frequencies for this locus for the different ethnic groups are 
shown in Table 4 and fig. 40. 
Table 5. Allele sizes, distribution and frequencies for locus DXS8113 










n n n 
Caucasian Frequency Mixed Frequency African 
ancestry 
0 0 1 0.012 0 
7 0.08 11 0.128 10 
13 0.148 18 0.209 3 
12 0.136 0 0 6 
15 0.17 33 0.384 40 
35 0.398 20 0.233 16 
6 0.068 3 0.035 1 
Allele Frequency Distribution for DXS8113 
0.6 
0.5 
.... 0.4 ... 



















Figure 40. Graphical presentation of the allele frequency distribution amongst 
the three populations for microsatellite marker DXS8113. 
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A summary of the overall allele sizes and frequencies for the 3 microsatellites are 
represented in table 5. 
Table 6. Summary of overall allele sizes and frequencies for the combined ethnic 
groups 
Summary of overall allele sizes and frequencies for the combined ethnic groups 
DXS8090 DXS1068 DXS8113 
Size # alleles Freq Size # alleles Freq Size # alleles Freq 
150 I 0.004 245 18 0.076 227 l 0.004 
152 4 0.016 247 20 0.084 229 28 0.112 
154 4 0.016 249 37 0.155 231 34 0.136 
156 8 0.031 251 29 0.122 233 18 0.072 
158 21 0.081 253 18 0.076 235 88 0.352 
160 22 0.085 255 29 0.122 237 71 0.284 
162 46 0.178 257 54 0.227 239 10 0.04 
164 29 0.112 259 33 0.139 
166 27 0. 105 
168 59 0.229 
170 26 0.101 
172 11 0.043 
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Microsatellite Heterozygosity Indices 
Microsatellite heterozygosity indices are a good predictor of the likelihood of a 
microsatellite marker being informative in family linkage studies such as prenatal 
diagnosis. The higher the index, the higher the probability of informativeness. 
These indices are tabulated in table 6. When calculating heterozygosity indices, 
the following formulas were used: 
Observed Heterozygosity = Heterozygotes 
Heterozygotes + Homozygotes 





Observed and expected heterozygosity indexes of each 
Microsatellite 
DXS8090 DXS1068 DXS8113 
Observed Expected Observed Expected Observed 
0.75 0.783 0.833 0.795 0.737 
0.85 0.857 0.75 0.833 0.778 






4.4. Discussion and Conclusion 
The impetus to look at microsatellites around the OTC gene stemmed from two 
requests from the parents of patient 3 for prenatal diagnosis in recent pregnancies. 
OTC deficiency cannot be diagnosed by measuring OTC activity from cultured 
arnniocytes or aminiotic fluid, and the only recourse in this family was thus, DNA 
linkage analysis using a X-chromosome genotypes as defined by those inherited 
by the affected and unaffected siblings (Ch 2, fig 10). The OTC gene mutation in 
this family was unknown at this stage and it was therefore necessary to look at the 
X-chromosome genotypes of closely associated and flanking microsatellites 
markers. 
Three microsatellites were selected for analysis and all gave readable gels after 
PCR and PAGE. Only one however, proved to be informative in this kindred in 
spite of high reported heterozygosity indexes. This microsatellite was 
successfully used to detect an affected male foetus in the first prenatal and a 
carrier female foetus in the second pregnancy. PCR of OTC exonic regions can 
now be used as an alternative approach should the parents again request pre-natal 
diagnosis, as the mutation in this family has subsequently been shown to be a 
large intragenic deletion, removing exons 5-10 (Ch 2, fig 21 ); diagnosis of an 
affected male foetus would thus be made on the inability to amplify product from 
these exons. 
The lack of informativeness for two of these microsatellites in kindred 3 was 
unexpected as heterozygosity indexes reported in the literature are all >0.68 
However, these indexes are from populations of European ancestry, and while 
they are likely to apply universally, it was deemed reasonable to determine their 
values in Africans and Mixed ancestry from South Africa and to examine their 
length diversities. These data would also allow for their ranking and thus order of 
selection in future prenatal testing. 
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Heterozygosity indexes were determined in a study cohort, which consisted of 91 
females, 27 of whom were African, 40 mixed ancestry and 24 Caucasian. Both 
the observed and expected indexes have been given in the results section, and 
while there was general agreement between the indexes, markers DXS8113 and 
DXS 1068 differed in the African and Mixed ancestry groups. While this may be 
indicative of some deviation from Hardy-Weinberg equilibrium, the small sample 
size examined would suggest that this is due to sampling error. For the purposes 
of microsatellite ranking it is better to work with the expected indexes as they take 
the length variations into account. 
The expected heterozygosity indexes observed for the three microsatellite markers 
were all in the high range and above 0.65, varying from 0.65 - 0.88. There is thus 
little reason to choose between these markers on the basis of their indexes, except 
perhaps in Africans where DXS8113 gave an index of 0.65. More important in 
microsatellite selection however, is the ease of amplification and the ability to 
score individual bands following PAGE and autoradiography for 
32P labelled PCR 
products. In this context, DXS8090 would the marker of choice as it gave the 
clearest bands (Fig 35A) and also gave the widest range of repeat lengths. 
In conclusion, the microsatellite markers used in this study have been found to be 
useful in the indirect analysis of the OTC gene and have allowed for the detection 
of an affected foetus in the first prenatal and a carrier foetus in the second. Ideally 
OTC deficiency in the first foetus should have been confirmed through a liver 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 8. List of Primers for the 10 OTC Exons. (5' - 3') 
OTCExon Forward Primer Reverse Primer 
I agttttcaagggcatagaatc gttttatgcatcaccatgattcc 
2 accatagtacatgggtcttttctg ggactggtagttaactggaac 
3 cacttatttgggggctagttatta gtcttcaccttcaatccctct 
4 gagatgatggccaattctttg tcagattctgaaatcagctttgg 
5 ggcattatttaagcataattatctt cacttaagcaagtcaggaatta 
6 ttcatctccttcatcccgtg gtgatttaagagaggggttagtttc 
7 aaataagatttaaattccttcctc aggcaataatagctttacat 
8 actgtcccatgaagttattta atttgttttcttctggccttca 
9 atagtcaaaaagtggtcttatccc atctcacttgcttattatttccc 
10 aggtccctaagcagactgtcg tcattctgttactgaagaacattgc 
The lyophilised primers were reconstituted in TE Buffer at stock concentrations of 
500pmoles/µl and stored at -70 °C. Working solutions were diluted to 
20pmoles/µl concentrations and stored at -20 °C. 
Table 9. MgCli Concentration and Temperature Profile. 
Exon MgCli Annealing 
Concentration Temperature 
I l.SmM 55°C 
2 1.SmM 55°C 
3 l .OmM 51°C 
4 l.SmM 55°C 
5 l.OmM 51 °C 
6 l .5mM 55°C 
7 I.OmM 51 °C 
8 l.5mM 51 °C 
9 l.5mM 55°C 
IO l.5mM 58°C 
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Ethidium Bromide 
1 OOOX Stock Solution (O.Smglml) 
50mg Ethidium Bromide in 1 OOml ddH20 
Working Ethidium Bromide (0.5ug/ml) 
Dilute stock solution 1 in 1000 (for gels) 
O.SM EDTA 
Dissolve 186.lg Na2EDTA.2H20 in 400ml ddH20, adjust pH to 8.0 with IOM 
NaOH (use NaOH pellets if necessary). Make up to 1 litre with dH20. 
SOX T AE Stock 
242g Tris base 
57.lml Glacial acetic acid 
lOOml 0.5M EDTA 
Make up to 1 litre with dH20 and Autoclave. 
lX Working T AE 
Dilute SOX stock TAE 1 in 50 with dH20 (lOml SOX TAE in 500ml dH20). 
lOX TBE Electrophoresis Buffer 
108g Tris base 
55g Boric acid 
40ml 0.5M EDT A 
Make up to 1 litre with dH20. 
lX Working TBE 
Dilute 1 OX Stock - 1 OOml in 1 litre dH20. 
TE Buffer 
IOmM TrisHCI pH 7.6 
lmM EDTA pH 8.0 (disodium salt) 
109 
lml lM Tris pH 7.6 and 200 µl 0.5M EDTA pH 8.0 were dissolved in lOOml 
dH20 . 
DNA Extraction Protocols 
EDT A Blood Extraction Method 
Low salt buffer (TKMl) 
lOmM Tris-HCL pH7.6 
lOmMKCL 
lOmMMgCh 
2mM EDTA (disodium salt) 
0.12lg Tris, 0.075g KCl, 0.203g MgCh and 0.075g EDTA were dissovled in 
lOOml ddH20 with pH adjusted to 7.6 with HCL 
Nonidet P-40 (Igepal) 
Supplied by Sigma, catalogue number I 3021 
High salt buffer (TKM2) 




2mM EDTA (disodium salt) 
0.121g Tris, 0.075g KCl, 0.203g MgCh, 2.338g NaCl and 0.075g EDTA were 
dissovled in lOOml ddH20 with pH adjusted to 7.6 with HCl. 
10% Sodium Dodecyl Sulphate (SDS) 
lOg SDS were dissolved in lOOml ddH20 . 
6MNaCI 




70rnl absolute ethanol and 30ml distilled water. 
DNA Extraction from Heparinized blood 
Heparin (Sigma I 000 units/ml) 
Cell lysis buffer pH 8.0 
0.32M Sucrose 
5mMMgCb 
lOmM TrisHCl pH 7.6 
1% Triton X-IOO 
I09.5g Sucrose, 5ml of IM MgCb and IOml of lM TrisHCl was dissolved in 
990ml of distilled water, autoclaved and while the buffer was warm, l Oml Triton 
X-100 was added and the mix was stored at 4°C. 
1 % Triton X-100 
109.5g Sucrose, 5ml of IM MgC12 and lOrnl Tris-HCI were dissolved in 990ml 
ddH20 , autoclaved and while the buffer was warm, add lOml Triton X-100 and 
store at 4 °C. 
Wash buffer 
lOmMNaCl 
lOmM EDTA (disodium salt) pH 8.0 
0.58g NaCl and 3.72g EDTA were dissolved in lOOOrnl ddH20 and stored at 4 °C. 
20% Sarkosyl Solution 
20g N-Lauroylsarkosine (sodium salt)(Sigma) were dissolved in lOml ddH20, 
aliquoted and stored at - 20 °C. 
111 
7.SM Ammonium Acetate 
57.81g Ammonium acetate were dissolved in lOOml ddH20 , aliquted and stored at 
-20 °C. 
6.0M Guanidinium Chloride 
57.32g Guanidinium chloride were dissolved in lOOml ddH20 and stored at 4 °C. 
DNA Extraction from cell cultures 
Saline 
0.9g NaCl in lOOml ddH20. 
lOOuMEDTA 
3.72mg EDTA (MW=372.24) in lOOml ddH20 . 
4M NaCl 
33.37g NaCl in lOOml ddH20. 
Saline/EDT A 
50ml lOOuM EDTA and 3.7ml 4M NaCl in 200ml ddH20. 
10% SDS 
1 Og SDS in 1 OOml ddH20. 
lOmg/ml Proteinase K 
lOOmg Proteinase K (from Tritirachium album) (Rouche) was dissolved in lOml 
distilled water, aliquoted and stored at 4°C. 
Proteinase K 
20mg Proteinase K/ml (Baeringer Mannheim # 1413 783 ). 
6MNaCl 
35.1 g NaCl in I OOml ddH20 . 
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Isopronanol 
Supplied by Merck, Catalogue number AB009634 
70% ethanol 
70ml absolute ethanol and 30ml dH20 
Polymerase Chain Reaction 
Materials and Reagents: 
Thermal Cycler 
O.Sml thin walled sterile microcentrifuge tubes. 
Deoxynucleotidetriphosphates ( dNTP's ): 
The following lyophilised Boehringer Mannheim products were used: 
dATP disodium salt Cat No. 103985 
dCTP disodium salt 
dGTP disodium salt 
dTTP trisodium salt 
Cat No. 104043 
Cat No. 104108 
Cat No. 104272 
Stock solutions were made in ultra pure water, the pH adjusted to 7.0 with 50mM 
Tris base made in ultra pure water and sterile filtered. The l OmM solutions were 
made from the stock solutions and 20ul of each 1 OmM dNTP stock solution were 
mixed to give a 2mM dNTP working solution. Stocks and working solutions were 
stored at -20 °C. 
MgCii (Sigma) 
A l .OOM MgC}z was diluted to 25mM in dH20. 
10 x PCR buff er 
The Promega stock solution was used. 
Taq DNA polymerase 
The Promega Taq was used (1 OU/ul). 
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Primer/DNA dilution buffer 
lOmM Tris pH 7.6 
lmMEDTA 
lml IM Tris pH 7.6 and 200 µl 0.5M EDTA pH 8.0 were dissolved in lOOml 
distilled water. The solution was filtered, aliquoted and stored at -20°C. 
DNA template 
Working stocks (O.lµg/µl) of the isolated DNA was made using DNA dilution 
buffer. 
Forward and Reverse Primers (See tablet) 
All primers were diluted in Primer dilution buffer. Stock solutions of 500pM was 
made of each primer and stored at -7 5°C. Working stocks of 20pM was used in 
the PCR reactions and stored @ -20°C. 
6 x DNA loading buffer 
0.25% Bromophenol blue 
30% Glycerol 
0.25g Bromophenol blue and 30ml glycerol was dissolved in a total volume of 
1 OOml distilled water and stored at 4°C. 
SSCP loading dye 
lOmMNaOH 
95% Formamide 
0.05% Bromophenol blue 
0.05% Xylene Cyanol 
9.5ml Formamide, 10µ1 lOM NaOH, 250µ12% Bromophenol blue and 250 µI 2% 
Xylene cyanol were all combined. 
Stock plate glue solution 




Dimethyl dichlorosilane solution (BDH), Catalogue number D3879 
Ultra pure urea 
Supplied by Sigma, Catalogue number U0631 
40% Acrylamide stock (39.6: 0.4) 
39.6g Acrylamide (BDH Laboratory Supplies) and 0.4g NN'-methylenebis-
acrylamide (BDH Laboratory Supplies) dissolved on a magnetic stirrer in lOOml 
ofdH20. 
30.8% Acrylamide stock (30 : 0.8) 
30g Acrylamide (BDH Laboratory Supplies) and 0.8g NN'-methylenebis-
acrylamide (BDH Laboratory Supplies) dissolved on the magnetic stirrer in 
1 OOml of dH20. 
10% APS (Sigma) 
O.lg Ammonium Persulphate (APS) dissolved in lml dH20. 
N ,N ,N' ,N' -Tetramethylethylenediamine (TE MED) (Pro mega) 




2g NaOH was dissolved in just less than 2 litres of distilled water, then 8ml of 
NH40H was added and covered while stirring gently to avoid evaporation of the 
NH3 
Immediately before use 2g AgN03 was added while stirring. 
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Developing solution 
0.005% Citric acid 
0.02% Formalin (34% stock) 
O.lg of the citric acid and 1.176ml of the formalin was dissolved in 2 litres of 
dH20. 
Solution! 
2g AgN03 was dissolved in 2 litres of dH20. 
Solution2 
30g of NaOH, 0.2g NaBH4 and 8ml formaldehyde was dissolved in 2 litres of 
dH20 . 
Solution 3 
15g Na2C03 was dissolved into 2 litres of dH20. 
Sequence Analysis 
40% Sucrose (w/v) 
1 Og of sucrose was dissolved in 25ml of dH20 , filtered, aliquoted and stored at -
20°c. 
1.0% Agarose gel 
1.0g (w/v) low melting point agarose (Whitehead Scientific) 
100 ml 1 x TAE 
2.5µ1 Ethidium Bromide 
30% Acrylamide (29:1) 
29g of Acrylamide and lg of NN'-methylenebis-acrylamide dissolved on the 
magnetic stirrer in 1 OOml of dH20 . 
RFLP and Southern Blot Analysis 
Restriction Enzymes 
Barn HI, Hind III, and Pvu II, supplied by Boerhinger and Mannheim. 
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Incubation Buffers for Restriction Enzymes 
0.25M HCI 
21.48 ml HCl was made up to a total volume of 1 OOOml ddH20 
0.4MNaOH 
16g NaOH were dissolved in lOOOml ddH20 
Nylon Membrane 
Nylon Hybond N+ membrane (Amersham) 
Whatman No. 3 Filter Paper 






18.6g Na2HP04, l .Oml EDTA(500mM), 35.0g SDS, and 5.0g BSA were dissolved 
in a total volume of 500ml with ddH20 . 
20X SSC Solution 
l 75.3g NaCl and 88.2g trisodium citrate were dissolved in a total volume of 
lOOOml with the pH adjusted to 7.0 with ION NaOH and autoclaved. 
10% Sodium Dodecyl Sultbate 
lOg SOS were dissolved in lOOml ddH20 . 
Wash Solutions: 
2XSSC/0.1 %SDS 
Mix 200ml 20XSSC and 20ml 10%SDS in a total volume of2000ml with ddH20. 
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0.2XSSC/0.1 %SOS 
Mix 20ml 20XSSC and 20ml 10%SDS in a total volume of2000ml with ddH20. 
Hyperfilm TM MP High Performance Autoradiography Film 
Supplied by Amersham Life Science 
X-inactivation 
10 x Buffer L 
Supplied by Promega in a l .5ml volume 
Hpa II enzyme 
Supplied by Promega with a concentration of 1 OU/µl in a 20ul volume 
Casein 
0.0076g Casein (Sigma) diluted in 7.6ml lOmM Tris pH 8.0 and had a 
concentration of lmg/ml. The reagent was then aliquoted and stored @ -20°C. 
Bovine Serum Albumin (BSA) 
Supplied by Promega to a final concentration ofO.lmg/ml 
Androgen primer forward (ANDR-f) 
Manufactured by Whitehead Scientific. Primers were diluted with primer dilution 
buffer to a final working concentration of 20pM/µl and stored at -20°C. 
5' TGC GCG AAG TGA TCC AGA ACC-3' 
Androgen primer reverse (ANDR-r) 
Manufactured by Whitehead Scientific. Primers were diluted with primer dilution 
buffer to a final working concentration of 20pM/µl and stored at -20°C. 
5' TGG GCT TGG GGA GAA CCA TCC -3' 
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DNA template 
Working stocks (0.5µg/µl) of the isolated DNA was made using DNA dilution 
buffer. 
20% Acrylamide (19:1) 
19g Acrylamide (BDH Laboratory Supplies) and l.Og NN'-methylenebis-
acrylamide (BDH Laboratory Supplies) dissolved on the magnetic stirrer in 
1 OOml of distilled water. 
Microsatellites 
10 x PNK buffer 
Supplied by the USB Corporation. 
-40 Primer 
Boehringer Mannheim manufactured the primer with a stock concentration of 
5µM. 
T4PNK 
The enzyme was supplied by the USB Corporation and had a stock concentration 
of 30U/µl. A working stock of T4 PNK was used at a concentration of 5U/µl. 
[y32P) ATP 
The radioactive [y32P] ATP stock was 150mCi/ml > 5000Ci/mrnol and was 
supplied by Arnersham PB 15068. 
M13 DNA single stranded 
Supplied by USB Corporation with a stock concentration of 0.2µg/µI 
Sequenase KIT 
Supplied by Boehringer Mannheim. A 1 :2 dilution of the sequenase was made 
before with pyrophosphate and briefly spun. 
119 
40% Acrylamide stock 
250.0g Acrylamide (BDH Laboratory Supplies) and 13.lg NN'-methylenebis-
acrylamide (BDH Laboratory Supplies) dissolved on a magnetic stirrer in 657ml 
of warm dH20, stored in a brown bottle @ 4°C. 
6% Polyacrylamide working solution 
A volume of 15.0ml 40% Polyacrylamide stock solution, 42.0g Urea, 10.0ml 10 x 
TBE and 33ml of water were mixed to give a final volume of 1 OOml of the 
working solution. This mix could only be stored for 2 weeks @ 4°C. 
10 x TBE 
108g Tris base, 55.0g Boric acid and 40ml of 0.5M EDTA (pH 8.0) dissolved in 
1 OOOml of dH20. 
Developer solution 
Stop solution 
2% acetic acid 
Fixer solution 
A 1 :3 dilution was made and the pH and silver content was checked. 
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